UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2020~~2021


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___.

Commission File No. 001-37392

Apollo Medical Holdings, Inc.

(Exact name of registrant as specified in its charter)


Delaware			95-4472349
(State or Other Jurisdiction			(I.R.S. Employer
of Incorporation)			Identification Number)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of principal executive offices and zip code)

(626) 282-0288

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, $0.001 par value per share

AMEH

Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes ☒ No

~~Securities registered pursuant to Section 12(b) of the Act:~~

~~Title of Each Class~~

~~Trading Symbol~~

~~Name of Each Exchange on Which Registered~~

~~Common Stock, $0.001 par value per share~~

~~AMEH~~

~~Nasdaq Capital Market~~

As of ~~November 2, 2020,~~October 26, 2021, there were ~~54,265,602~~55,549,053 shares of common stock of the registrant, $0.001 par value per share, issued and ~~outstanding~~.outstanding.

APOLLO MEDICAL HOLDINGS, INC.

INDEX TO FORM 10-Q FILING

TABLE OF CONTENTS


		PAGE
	Introductory Note	4
	Note About Forward-Looking Statements	4

	PART I FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements ~~– Unaudited~~	4
	Consolidated Balance Sheets as of September 30, 2021 ~~September~~ ~~30, 2020~~ and December 31, ~~2019~~2020	5
	Consolidated Statements of ~~Income~~Operations for the Three and Nine Months Ended September 30, ~~2020~~2021 and ~~2019~~2020	78
	Consolidated Statements of Mezzanine and Stockholders ’ Equity for the Three and Nine Months Ended September 30, ~~2020~~2021 and ~~2019~~2020	89
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, ~~2020~~2021 and ~~2019~~2020	1011
	Notes to Consolidated Financial Statements	1213
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	51
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	6564
Item 4.	Controls and Procedures	65

	PART II OTHER INFORMATION

Item 1.	Legal Proceedings	6766
Item 1A.	Risk Factors	6766
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	6866
Item 3.	Defaults Upon Senior Securities	6866
Item 4.	Mine Safety Disclosures	6866
Item 5.	Other Information	6866
Item 6.	Exhibits	6867

Glossary

The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:


Accountable Health Care			Accountable Health Care IPA, a Professional Medical Corporation
AHMC			AHMC Healthcare Inc.
AIPBP			All-Inclusive Population-Based Payments
AKM			AKM Medical Group, Inc.
Alpha Care			Alpha Care Medical Group, Inc.
AMG			AMG, a Professional Medical Corporation
AMG Properties			AMG Properties, LLC
AMH			ApolloMed Hospitalists, a Medical Corporation
AMM			Apollo Medical Management, Inc.
AP-AMH			AP-AMH Medical Corporation
AP-AMH 2			AP-AMH 2 Medical Corporation
APAACO			APA ACO, Inc.
APC			Allied Physicians of California, a Professional Medical Corporation
APCMG			Access Primary Care Medical Group
APC-LSMA			APC-LSMA Designated Shareholder Medical Corporation

BAHA			Bay Area Hospitalist Associates
~~Bright~~CAIPA MSO			~~Bright Health Company of California, Inc.~~CAIPA MSO, LLC
CDSC			Concourse Diagnostic Surgery Center, LLC
CMS			Centers for Medicare & Medicaid Services
CQMC			Critical Quality Management Corporation
CSI			College Street Investment LP, a California limited partnership
DMHC			California Department of Managed Healthcare
DMG			Diagnostic Medical Group of Southern California
HSMSO			Health Source MSO Inc., a California corporation

ICC			AHMC International Cancer Center, a Medical Corporation
IPA			independent practice association
LMA			LaSalle Medical Associates
MMG			Maverick Medical Group, Inc.
MPP			Medical Property Partners, LLC
NGACO			Next Generation Accountable Care Organization
NMM			Network Medical Management, Inc.
~~PASC~~			~~Pacific Ambulatory Health Care, LLC~~
PMIOC			Pacific Medical Imaging and Oncology Center, Inc.
SCHC			Southern California Heart Centers
Sun Labs			Sun Clinical Laboratories
Tag 6			Tag-6 Medical Investments Group, LLC
Tag 8			Tag-8 Medical Investments Group, LLC
UCAP			Universal Care Acquisition Partners, LLC
UCI			Universal Care, Inc.
VIE			variable interest entity
ZLL			ZLL Partners, LLC

INTRODUCTORY NOTE

Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the “Company,” “we,” “us,” “our,” and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”) and “ApolloMed” refers to Apollo Medical Holdings, Inc.

The Centers for Medicare & Medicaid Services (“CMS”) have not reviewed any statements contained in this Quarterly Report on Form 10-Q describing the participation of APA ACO, Inc. (“APAACO”) in the Next Generation Accountable Care Organization (“NGACO”) Model.

Trade names and trademarks of the Company and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.

NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, statements about the ~~Company's~~Company’s guidance for the year ending December 31, ~~2020,~~2021, any statements about our business (including the impact of the ~~2019 Novel Coronavirus (COVID-19)~~COVID-19 pandemic on our business), financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, such as our projected capitation from CMS for the year ending December 31, ~~2020~~2021, or otherwise, and our future liquidity, including cash ~~flows and any payments under the $545.0 million loan we made to our VIE, AP-AMH;~~flows; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; any statements regarding the outlook on our NGACO Model or strategic transactions; any statements regarding management’s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “think,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “contemplate,” “budgeted,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.

Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended December 31, ~~2019,~~2020, filed with the ~~SEC~~Securities and Exchange Commission (the “SEC”) on March ~~16, 2020,~~15, 2021, including the risk factors discussed under the heading “Risk Factors” in Part I, Item IA thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements.

PART I FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS ~~- UNAUDITED~~

~~Table of Contents~~

APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(UNAUDITED)


		September 30, 2020		December 31, 2019			September 30, 2021		December 31, 2020

Assets	Assets					Assets

Current assets	Current assets					Current assets
Cash and cash equivalents	Cash and cash equivalents	$	166,082	$	103,189	Cash and cash equivalents	$	204,768	$	193,470
Restricted cash		0		75
Investment in marketable securities		118,309		116,539

Investments in marketable securities						Investments in marketable securities	128,558		67,695
Receivables, net	Receivables, net	18,257		11,004		Receivables, net	18,753		7,058
Receivables, net – related parties	Receivables, net – related parties	41,518		48,136		Receivables, net – related parties	53,626		49,260
Other receivables	Other receivables	3,988		16,885		Other receivables	5,773		4,297
Prepaid expenses and other current assets	Prepaid expenses and other current assets	12,119		10,315		Prepaid expenses and other current assets	11,734		16,797
Loan receivable		6,425		6,425
Loan receivable – related parties		0		16,500
Loan receivable – related party						Loan receivable – related party	4,000		—

Total current assets	Total current assets	366,698		329,068		Total current assets	427,212		338,577

Noncurrent assets	Noncurrent assets					Noncurrent assets
Restricted cash		746		746
Land, property and equipment, net		10,929		12,130
Land, property, and equipment, net						Land, property, and equipment, net	49,280		29,890
Intangible assets, net	Intangible assets, net	90,781		103,012		Intangible assets, net	83,594		86,985
Goodwill	Goodwill	239,053		238,505		Goodwill	243,353		239,053
Investment in other entities – equity method		27,220		28,427
Loans receivable						Loans receivable	584		480
Loans receivable – related party						Loans receivable – related party	—		4,145
Investments in other entities – equity method						Investments in other entities – equity method	45,046		43,292
Investments in privately held entities	Investments in privately held entities	37,075		896		Investments in privately held entities	896		37,075
Restricted cash						Restricted cash	—		500
Operating lease right-of-use assets	Operating lease right-of-use assets	19,298		14,248		Operating lease right-of-use assets	16,134		18,574
Other assets	Other assets	22,473		1,681		Other assets	5,195		18,915

Total noncurrent assets	Total noncurrent assets	447,575		399,645		Total noncurrent assets	444,082		478,909

Total assets (1)	Total assets (1)	$	814,273	$	728,713	Total assets (1)	$	871,294	$	817,486

Liabilities, mezzanine equity and stockholders’ equity
Liabilities, mezzanine equity, and stockholders’ equity						Liabilities, mezzanine equity, and stockholders’ equity

Current liabilities	Current liabilities					Current liabilities

Accounts payable and accrued expenses	Accounts payable and accrued expenses	$	40,474	$	27,279	Accounts payable and accrued expenses	$	57,505	$	36,143
Fiduciary accounts payable	Fiduciary accounts payable	3,986		2,027		Fiduciary accounts payable	8,827		9,642
Medical liabilities	Medical liabilities	57,455		58,725		Medical liabilities	42,872		50,330
Income taxes payable	Income taxes payable	16,169		4,529		Income taxes payable	4,024		4,224
Dividend payable	Dividend payable	485		271		Dividend payable	556		485
Finance lease liabilities	Finance lease liabilities	102		102		Finance lease liabilities	110		102
Operating lease liabilities	Operating lease liabilities	3,290		2,990		Operating lease liabilities	2,658		3,177

~~Table of Contents~~


		September 30, 2020		December 31, 2019			September 30, 2021		December 31, 2020

Current portion of long-term debt	Current portion of long-term debt	9,500		9,500		Current portion of long-term debt	207		10,889

Total current liabilities	Total current liabilities	131,461		105,423		Total current liabilities	116,759		114,992

Noncurrent liabilities	Noncurrent liabilities					Noncurrent liabilities
Deferred tax liability	Deferred tax liability	11,659		18,269		Deferred tax liability	19,592		10,959
Finance lease liabilities, net of current portion	Finance lease liabilities, net of current portion	337		416		Finance lease liabilities, net of current portion	221		311
Operating lease liabilities, net of current portion	Operating lease liabilities, net of current portion	16,616		11,373		Operating lease liabilities, net of current portion	13,856		15,865
Long-term debt, net of current portion and deferred financing costs	Long-term debt, net of current portion and deferred financing costs	226,051		232,172		Long-term debt, net of current portion and deferred financing costs	182,813		230,211
Other long-term liabilities						Other long-term liabilities	6,232		—

Total noncurrent liabilities	Total noncurrent liabilities	254,663		262,230		Total noncurrent liabilities	222,714		257,346

Total liabilities (1)	Total liabilities (1)	386,124		367,653		Total liabilities (1)	339,473		372,338

Commitments and contingencies (Note 11)
Commitments and contingencies (Note 12)						Commitments and contingencies (Note 12)	0

Mezzanine equity
0Mezzanine equity						0Mezzanine equity
Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation	Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation	198,731		168,725		Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation	91,500		114,237

Stockholders’ equity	Stockholders’ equity					Stockholders’ equity
Series A Preferred stock, $0.001 par value per share; 5,000,000 shares authorized (inclusive of all preferred stock, including Series B Preferred stock); 1,111,111 issued and 0 outstanding		0		0
Series B Preferred stock, $0.001 par value per share; 5,000,000 shares authorized (inclusive of all preferred stock, including Series A Preferred stock); 555,555 issued and 0 outstanding		0		0
Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,775,817 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, as of September 30, 2020 and December 31, 2019, respectively		37		36
Series A Preferred stock, $0.001 par value per share; 5,000,000 shares authorized (inclusive of all preferred stock, including Series B Preferred stock); 1,111,111 issued and zero outstanding						Series A Preferred stock, $0.001 par value per share; 5,000,000 shares authorized (inclusive of all preferred stock, including Series B Preferred stock); 1,111,111 issued and zero outstanding	—		—
Series B Preferred stock, $0.001 par value per share; 5,000,000 shares authorized (inclusive of all preferred stock, including Series A Preferred stock); 555,555 issued and zero outstanding						Series B Preferred stock, $0.001 par value per share; 5,000,000 shares authorized (inclusive of all preferred stock, including Series A Preferred stock); 555,555 issued and zero outstanding	—		—
Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,397,050 and 42,249,137 shares issued and outstanding, excluding 10,925,702 and 12,323,164 treasury shares, as of September 30, 2021 and December 31, 2020, respectively						Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,397,050 and 42,249,137 shares issued and outstanding, excluding 10,925,702 and 12,323,164 treasury shares, as of September 30, 2021 and December 31, 2020, respectively	44		42
Additional paid-in capital	Additional paid-in capital	168,653		159,608		Additional paid-in capital	305,994		261,011
Retained earnings	Retained earnings	59,714		31,905		Retained earnings	129,859		69,771
		228,404		191,549			435,897		330,824

Noncontrolling interest	Noncontrolling interest	1,014		786		Noncontrolling interest	4,424		87

Total stockholders’ equity	Total stockholders’ equity	229,418		192,335		Total stockholders’ equity	440,321		330,911

Total liabilities, mezzanine equity and stockholders’ equity		$	814,273	$	728,713
Total liabilities, mezzanine equity, and stockholders’ equity						Total liabilities, mezzanine equity, and stockholders’ equity	$	871,294	$	817,486

The accompanying notes are an integral part of these unaudited consolidated financial statements.

(1) The ~~Company's~~Company’s consolidated balance sheets include the assets and liabilities of its consolidated ~~variable interest entities ("VIEs").~~VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling ~~$877.6~~$601.8 million and ~~$849.3~~$576.1 million as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of ~~$113.0~~$92.8 million and ~~$114.5~~$88.6 million as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. The VIE balances do not include $994.8 million of investment in affiliates and $15.8 million of amounts due from affiliates as of September 30, 2021 and $225.1 million of investment in affiliates and $22.7 million of amounts due to affiliates as of December 31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 1516 – Variable Interest Entities (VIEs) for further detail.

~~Table of Contents~~

APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF ~~INCOME~~OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

(UNAUDITED)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019		2020		2019			2021		2020		2021		2020
Revenue	Revenue									Revenue
Capitation, net	Capitation, net	$	135,032	$	130,807	$	416,402	$	305,548	Capitation, net	$	149,059	$	135,032	$	438,350	$	416,402
Risk pool settlements and incentives	Risk pool settlements and incentives	30,916		11,355		54,155		32,640		Risk pool settlements and incentives	59,923		30,916		94,146		54,155
Management fee income	Management fee income	8,707		8,518		26,212		27,867		Management fee income	9,652		8,707		26,345		26,212
Fee-for-service, net	Fee-for-service, net	3,737		4,100		9,434		12,059		Fee-for-service, net	7,260		3,737		14,968		9,434
Other income	Other income	1,731		1,280		4,194		3,753		Other income	1,223		1,731		5,006		4,194

Total revenue	Total revenue	180,123		156,060		510,397		381,867		Total revenue	227,117		180,123		578,815		510,397

Operating expenses	Operating expenses									Operating expenses
Cost of services		121,823		131,130		402,106		315,925
Cost of services, excluding depreciation and amortization										Cost of services, excluding depreciation and amortization	147,473		121,823		424,303		402,106
General and administrative expenses	General and administrative expenses	16,270		7,950		39,660		30,031		General and administrative expenses	21,813		16,270		45,476		39,660
Depreciation and amortization	Depreciation and amortization	4,674		4,920		14,004		13,793		Depreciation and amortization	4,671		4,674		13,105		14,004
Provision for doubtful accounts		0		0		0		(1,363)
Impairment of intangibles		0		1,994		0		1,994

Total expenses	Total expenses	142,767		145,994		455,770		360,380		Total expenses	173,957		142,767		482,884		455,770

Income from operations	Income from operations	37,356		10,066		54,627		21,487		Income from operations	53,160		37,356		95,931		54,627

Other (expense) income	Other (expense) income									Other (expense) income
Income from equity method investments		403		2,054		3,291		1,162
Income (loss) from equity method investments										Income (loss) from equity method investments	132		403		(3,680)		3,291
Gain on sale of equity method investment	Gain on sale of equity method investment	0		0		99,647		0		Gain on sale of equity method investment	2,193		—		2,193		99,647
Interest expense	Interest expense	(2,466)		(828)		(8,007)		(1,350)		Interest expense	(967)		(2,466)		(4,343)		(8,007)
Interest income	Interest income	752		509		2,544		1,305		Interest income	420		752		1,331		2,544
Other income		130		2,620		1,514		2,832
Unrealized (loss) gain on investments										Unrealized (loss) gain on investments	(60,943)		—		22,826		—
Other income (expense)										Other income (expense)	500		130		(14,080)		1,514

Total other (expense) income, net	Total other (expense) income, net	(1,181)		4,355		98,989		3,949		Total other (expense) income, net	(58,665)		(1,181)		4,247		98,989

Income before provision for income taxes		36,175		14,421		153,616		25,436
(Loss) income before (benefit from) provision for income taxes										(Loss) income before (benefit from) provision for income taxes	(5,505)		36,175		100,178		153,616

Provision for income taxes		10,751		3,682		44,204		6,483
(Benefit from) provision for income taxes										(Benefit from) provision for income taxes	(120)		10,751		31,575		44,204

Net income		25,424		10,739		109,412		18,953
Net (loss) income										Net (loss) income	(5,385)		25,424		68,603		109,412

Net income attributable to noncontrolling interest		8,711		7,035		81,603		11,564
Net (loss) income attributable to noncontrolling interest										Net (loss) income attributable to noncontrolling interest	(39,664)		8,711		8,515		81,603

Net income attributable to Apollo Medical Holdings, Inc.	Net income attributable to Apollo Medical Holdings, Inc.	$	16,713	$	3,704	$	27,809	$	7,389	Net income attributable to Apollo Medical Holdings, Inc.	$	34,279	$	16,713	60,088		$	27,809

Earnings per share – basic	Earnings per share – basic	$	0.46	$	0.11	$	0.77	$	0.21	Earnings per share – basic	$	0.77	$	0.46	$	1.38	$	0.77

Earnings per share – diluted	Earnings per share – diluted	$	0.45	$	0.10	$	0.75	$	0.20	Earnings per share – diluted	$	0.74	$	0.45	$	1.33	$	0.75

The accompanying notes are an integral part of these unaudited consolidated financial statements.

~~Table of Contents~~

APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS’ EQUITY

(IN THOUSANDS, EXCEPT SHARE DATA)

(UNAUDITED)


		Mezzanine Equity – Noncontrolling Interest in APC													Retained Earnings												Mezzanine Equity – Noncontrolling Interest in APC														Retained Earnings
				Common Stock Outstanding						Additional Paid-in Capital							Noncontrolling Interest				Shareholders’ Equity								Common Stock Outstanding						Additional Paid-in Capital								Noncontrolling Interest				Stockholders’ Equity
				Shares			Amount				Retained Earnings												Shares						Amount				Retained Earnings
Balance at January 1, 2020				$	168,725		35,908,057						$	36			$	159,608				$	31,905		$	786				$	192,335
Net (loss) income				(1,161)			—			—					—				4,052		95					4,147
Purchase of treasury shares		—				(16,897)		—			(301)				—				—				(301)
Purchase of noncontrolling interest		(125)				—		—			—				—				—				0
Shares issued for exercise of options and warrants		—				151,601		—			722				—				—				722
Share-based compensation		—				—		—			1,058				—				—				1,058
Dividends		(10,000)				—		—			—				—				—				0
Balance at March 31, 2020		$	157,439			36,042,761		$	36		$	161,087			$	35,957			$	881			$	197,961
Balance at January 1, 2021																										Balance at January 1, 2021	$	114,237				42,249,137			$	42			$	261,011			$	69,771			$	87			$	330,911
Net income	Net income	73,667				—		—			—				7,044				291				7,335			Net income	760					—			—				—				13,151				547				13,698
Purchase of noncontrolling interest	Purchase of noncontrolling interest	(126)				—		—			—				—				—				0			Purchase of noncontrolling interest	(150)					—	—				—				—				(75)				(75)
Cancellation of restricted stock awards																										Cancellation of restricted stock awards	—					(5,281)	—				(144)				—				—				(144)
Shares issued for vesting of restricted stock awards	Shares issued for vesting of restricted stock awards	—				24,453		—			—				—				—				0			Shares issued for vesting of restricted stock awards	—					7,689	—				—				—				—				—
Shares issued for exercise of options and warrants	Shares issued for exercise of options and warrants	—				242,299		—			2,283				—				—				2,283			Shares issued for exercise of options and warrants	—					421,002	1				4,255				—				—				4,256
Repurchase of treasury shares by noncontrolling interest																										Repurchase of treasury shares by noncontrolling interest	—					(34,158)	—				(342)				—				—				(342)
Share-based compensation	Share-based compensation	—				—		—			852				—				—				852			Share-based compensation	—					—	—				1,346				—				—				1,346
Sales of noncontrolling interest																										Sales of noncontrolling interest	—					—	—				—				—				37				37
Balance at March 31, 2021																										Balance at March 31, 2021	$	114,847				42,638,389	$	43			$	266,126			$	82,922			$	596			$	349,687
Net income																										Net income	46,859					—	—				—				12,658				13				12,671
Cancellation of restricted stock awards	Cancellation of restricted stock awards	—				—		—			(236)				—				—				(236)			Cancellation of restricted stock awards	—					(5,426)	—				(189)				—				—				(189)
Shares issued for vesting of restricted stock awards																										Shares issued for vesting of restricted stock awards	—					22,284	—				—				—				—				—
Shares issued for exercise of options and warrants																										Shares issued for exercise of options and warrants	—					53,504	—				561				—				—				561
Repurchase of treasury shares by noncontrolling interest																										Repurchase of treasury shares by noncontrolling interest	—					(100,000)	—				(2,450)				—				—				(2,450)
Share-based compensation																										Share-based compensation	—					—	—				1,556				—				—				1,556
Sale of noncontrolling interest																										Sale of noncontrolling interest	150					—	—				—				—				—				—
Sale of shares by noncontrolling interest																										Sale of shares by noncontrolling interest	—					1,638,045	1				40,132				—				—				40,133
Investment in noncontrolling interest																										Investment in noncontrolling interest	—					—	—				—				—				3,769				3,769
Dividends	Dividends	(20,000)				—		—			—				—				(347)				(347)			Dividends	(20,000)					—	—				—				—				(1,156)				(1,156)
Balance at June 30, 2020		$	210,980			36,309,513		$	36		$	163,986			$	43,001			$	825			$	207,848
Balance at June 30, 2021																										Balance at June 30, 2021	$	141,856				44,246,796	$	44			$	305,736			$	95,580			$	3,222			$	404,582
Net income	Net income	8,522				—		—			—				16,713				189				16,902			Net income	(40,356)					—	—				—				34,279				692				34,971
Purchase of noncontrolling interest		(771)				—		—			—				—				—				0
Shares issued for cashless exercise of warrants		—				66,517		—			—				—				—				0
Shares issued for exercise of options and warrants	Shares issued for exercise of options and warrants	—				399,787		1			4,019				—				—				4,020			Shares issued for exercise of options and warrants	—					190,254	—				1,785				—				—				1,785
Repurchase of treasury shares by noncontrolling interest																										Repurchase of treasury shares by noncontrolling interest	—					(40,000)	—				(2,947)				—				—				(2,947)
Share-based compensation	Share-based compensation	—				—		—			648				—				—				648			Share-based compensation	—					—	—				1,420				—				—				1,420
Acquisition of noncontrolling interest																										Acquisition of noncontrolling interest	—					—	—				—				—				500				500
Noncontrolling interest capital charge																										Noncontrolling interest capital charge	—					—	—				—				—				10				10
Dividends	Dividends	(20,000)				—		—			—				—				—				0			Dividends	(10,000)					—	—				—				—				—				—
Balance at September 30, 2020		$	198,731			36,775,817		$	37		$	168,653			$	59,714			$	1,014			$	229,418
Balance at September 30, 2021																										Balance at September 30, 2021	$	91,500				44,397,050	$	44			$	305,994			$	129,859			$	4,424			$	440,321

~~Table of Contents~~


		Mezzanine Equity – Noncontrolling Interest in APC													Retained Earnings												Mezzanine Equity – Noncontrolling Interest in APC														Retained Earnings
				Common Stock Outstanding						Additional Paid-in Capital							Noncontrolling Interest				Shareholders’ Equity								Common Stock Outstanding								Additional Paid-in Capital						Noncontrolling Interest				Stockholders’ Equity
				Shares			Amount				Retained Earnings												Shares						Amount						Retained Earnings
Balance at January 1, 2019				$	225,117		34,578,000						$	35			$	162,723				$	17,788		$	998				$	181,544
Balance at January 1, 2020																							Balance at January 1, 2020		$	168,725			35,908,057				$	36				$	159,608		$	31,905	$	786			$	192,335
Net (loss) income	Net (loss) income			(3,000)			—			—					—				140				410					550		Net (loss) income		(1,160)					—			—			—				4,052				95	4,147
Purchase of noncontrolling interest																										Purchase of noncontrolling interest	(126)					—			—			—			—				—				—
Purchase of treasury shares	Purchase of treasury shares	(40)				(93,000)		—			—				—				—				0			Purchase of treasury shares	—					(16,897)			—			(301)											(301)
Shares issued for exercise of options and warrants	Shares issued for exercise of options and warrants	155				17,000		—			140				—				—				140			Shares issued for exercise of options and warrants	—					151,601			—			722			—				—				722
Share-based compensation	Share-based compensation	202				2,000		—			143				—				—				143			Share-based compensation	—					—			—			1,058			—				—				1,058
Dividends	Dividends	(10,000)				—		—			—				—				—				0			Dividends	(10,000)					—			—			—			—				—				—
Balance at March 31, 2019		$	212,434			34,504,000		$	35		$	163,006			$	17,928			$	1,408			$	182,377
Balance at March 31, 2020																										Balance at March 31, 2020	$	157,439				36,042,761			$	36		$	161,087		$	35,957			$	881			$	197,961
Net income	Net income	6,896				—		—			—				3,545				223				3,768			Net income	73,666					—			—			—			7,044				291				7,335
Purchase of noncontrolling interest																										Purchase of noncontrolling interest	(125)					—			—			—			—				—				—
Shares issued for vesting of restricted stock awards																										Shares issued for vesting of restricted stock awards	—					24,453			—			—			—				—				—
Shares issued for exercise of options and warrants	Shares issued for exercise of options and warrants	50				135,000		—			758				—				—				758			Shares issued for exercise of options and warrants	—					242,299			—			2,283			—				—				2,283
Share-based compensation	Share-based compensation	203				—		—			128				—				—				128			Share-based compensation	—					—			—			852			—				—				852
Cancellation of restricted stock awards																										Cancellation of restricted stock awards	—					—			—			(236)			—				—				(236)
Dividends	Dividends	—				—		—			—				—				(942)				(942)			Dividends	(20,000)					—			—			—			—				(347)				(347)
Balance at June 30, 2019		$	219,583			34,639,000		$	35		$	163,892			$	21,473			$	689			$	186,089
Balance at June 30, 2020																										Balance at June 30, 2020	$	210,980				36,309,513			$	36		$	163,986		$	43,001			$	825			$	207,848
Net income	Net income	6,285				—		—			—				3,704				751				4,455			Net income	8,522					—	—		—			—			16,713				189				16,902
Purchase of noncontrolling interest																										Purchase of noncontrolling interest	(771)					—			—			—			—				—				—
Shares issued for cashless exercise of warrants																										Shares issued for cashless exercise of warrants	—					66,517			—			—			—				—				—
Shares issued for exercise of options and warrants	Shares issued for exercise of options and warrants	—				184,000		—			1,502				—				—				1,502			Shares issued for exercise of options and warrants	—					399,787			1			4,019			—				—				4,020
Share-based compensation	Share-based compensation	202				—		—			128				—				—				128			Share-based compensation	—					—			—			648			—				—				648
Stock subscriptions		550				—		—			—				—				—				0
Stock issued in connection with a business combination		414				—		—			—				—				—				0
Cost related to issuance of preferred shares		(804)				—		—			—				—				—				0
Cancellation of restricted stock awards																										Cancellation of restricted stock awards	—					—			—			—			—				—				—
Dividends	Dividends	(50,000)				—		—			—				—				—				0			Dividends	(20,000)					—			—			—			—				—				—
Balance at September 30, 2019		$	176,230			34,823,000		$	35		$	165,522			$	25,177			$	1,440			$	192,174
Balance at September 30, 2020																										Balance at September 30, 2020	$	198,731				36,775,817			$	37		$	168,653		$	59,714			$	1,014			$	229,418

The accompanying notes are an integral part of these unaudited consolidated financial statements.

910

~~Table of Contents~~

APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)


		Nine Months Ended September 30,					Nine Months Ended September 30,
		2020		2019			2021		2020
Cash flows from operating activities	Cash flows from operating activities					Cash flows from operating activities
Net income	Net income	$	109,412	$	18,953	Net income	$	68,603	$	109,412
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:						Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	Depreciation and amortization	14,004		13,793		Depreciation and amortization	13,105		14,004
Impairment of intangibles		0		1,994

Amortization of debt issuance costs	Amortization of debt issuance costs	1,004		0		Amortization of debt issuance costs	900		1,004
Provision for doubtful accounts		0		(1,363)
Share-based compensation	Share-based compensation	2,558		1,006		Share-based compensation	4,322		2,558
Unrealized loss (gain) from investment in equity securities		23		(6)
Income from equity method investments		(3,291)		(1,162)
Gain on sale of equity method investments		(99,647)		0
Gain on loan assumption		0		(2,250)
Unrealized (gain) loss from investment in equity securities						Unrealized (gain) loss from investment in equity securities	(22,826)		23
Loss (income) from equity method investments						Loss (income) from equity method investments	3,680		(3,291)
Gain on sale of equity method investment						Gain on sale of equity method investment	(2,193)		(99,647)
Impairment of beneficial interest						Impairment of beneficial interest	15,723		—
Loss on interest rate swaps						Loss on interest rate swaps	1,069		—
Deferred tax	Deferred tax	(6,137)		(186)		Deferred tax	6,847		(6,137)
Other						Other	189		—
Changes in operating assets and liabilities, net of business combinations:	Changes in operating assets and liabilities, net of business combinations:					Changes in operating assets and liabilities, net of business combinations:
Receivables, net	Receivables, net	(6,953)		1,904		Receivables, net	(10,686)		(6,953)
Receivables, net – related parties	Receivables, net – related parties	6,618		5,864		Receivables, net – related parties	(4,367)		6,618
Other receivables	Other receivables	12,898		(13,719)		Other receivables	(1,477)		12,898
Prepaid expenses and other current assets	Prepaid expenses and other current assets	(1,804)		(2,914)		Prepaid expenses and other current assets	5,064		(1,804)
Right-of-use assets	Right-of-use assets	2,601		1,877		Right-of-use assets	2,440		2,601
Other assets	Other assets	(5,090)		(525)		Other assets	(954)		(5,090)
Accounts payable and accrued expenses	Accounts payable and accrued expenses	12,644		4,868		Accounts payable and accrued expenses	14,362		12,644
Fiduciary accounts payable	Fiduciary accounts payable	1,958		196		Fiduciary accounts payable	(815)		1,958
Medical liabilities	Medical liabilities	(1,566)		(6,226)		Medical liabilities	(7,633)		(1,566)
Income taxes payable	Income taxes payable	11,642		(10,229)		Income taxes payable	(300)		11,642
Operating lease liabilities	Operating lease liabilities	(2,110)		(1,790)		Operating lease liabilities	(2,528)		(2,110)

Net cash provided by operating activities	Net cash provided by operating activities	48,764		10,085		Net cash provided by operating activities	82,525		48,764

Cash flows from investing activities	Cash flows from investing activities					Cash flows from investing activities
Payments for business acquisition, net of cash acquired	Payments for business acquisition, net of cash acquired	0		(49,403)		Payments for business acquisition, net of cash acquired	(2,575)		—
Proceeds from repayment of loans receivable – related parties	Proceeds from repayment of loans receivable – related parties	16,500		0		Proceeds from repayment of loans receivable – related parties	41		16,500
Advances on loans receivable		0		(7,425)
Purchases of marketable securities	Purchases of marketable securities	(1,793)		(20)		Purchases of marketable securities	(1,009)		(1,793)
Purchases of investments – equity method		(500)		(2,949)
Purchase of investment – equity method						Purchase of investment – equity method	(13,384)		(500)
Proceeds from sale of equity method investment	Proceeds from sale of equity method investment	52,743		0		Proceeds from sale of equity method investment	6,375		52,743
Purchases of property and equipment	Purchases of property and equipment	(553)		(807)		Purchases of property and equipment	(16,420)		(553)
Dividend received		0		240
Net cash provided by (used in) investing activities		66,397		(60,364)
Proceeds from sale of marketable securities						Proceeds from sale of marketable securities	1,106		—
Cash received from consolidation of VIE						Cash received from consolidation of VIE	3,322		—
Net cash (used in) provided by investing activities						Net cash (used in) provided by investing activities	(22,544)		66,397

Cash flows from financing activities	Cash flows from financing activities					Cash flows from financing activities
Repayment of bank loan and lines of credit		0		(52,640)
Dividends paid						Dividends paid	(31,089)		(50,133)
Repayment of long-term debt						Repayment of long-term debt	(238,254)		(7,125)
Payment of finance lease obligations						Payment of finance lease obligations	(81)		(78)
Proceeds from the exercise of stock options and warrants						Proceeds from the exercise of stock options and warrants	6,601		6,552
Repurchase of shares						Repurchase of shares	(5,739)		(1,559)

1011

~~Table of Contents~~

Nine Months Ended September 30,
2020 2019
Dividends paid (50,133) (60,670)
Repayment of term loan (7,125) 0
Payment of finance lease obligations (78) (76)
Proceeds from the exercise of stock options and warrants 6,552 2,400
Repurchase of shares (1,559) (40)
Borrowings on line of credit 0 289,600
Proceeds from common stock offering 0 755
Cost of debt and equity issuance costs 0 (5,622)
Net cash (used in) provided by financing activities (52,343) 173,707
Net increase in cash, cash equivalents and restricted cash 62,818 123,428
Cash, cash equivalents and restricted cash, beginning of period 104,010 107,637
Cash, cash equivalents and restricted cash, end of period $ 166,828 $ 231,065
Supplementary disclosures of cash flow information:
Cash paid for income taxes $ 37,900 $ 17,900
Cash paid for interest 6,961 1,000
Supplemental disclosures of non-cash investing and financing activities
Dividend declared included in dividend payable $ 485 $ 271
Deferred tax liability adjustment to goodwill $ 0 $ 11,540
Deferred tax liability adjustment related to warrant exercises $ 473 $ 0
APC stock issued in exchange for AMG $ 0 $ 414
Preferred shares received from sale of equity method investment $ 36,179 $ 0


	Nine Months Ended September 30,
	2021		2020
Distribution to noncontrolling interest	(75)		—
Proceeds from sale of noncontrolling interest	48		—
Borrowings on revolver	180,000		—
Proceeds from sale of shares	40,133		—
Payment of debt issuance costs	(727)		—
Net cash used in financing activities	(49,183)		(52,343)

Net increase in cash, cash equivalents, and restricted cash	10,798		62,818

Cash, cash equivalents, and restricted cash, beginning of period	193,970		104,010

Cash, cash equivalents, and restricted cash, end of period	$	204,768	$	166,828

Supplementary disclosures of cash flow information:
Cash paid for income taxes	$	24,800	$	37,900
Cash paid for interest	3,330		6,961

Supplemental disclosures of non-cash investing and financing activities
Dividend declared included in dividend payable	$	71	$	485
Preferred shares received from sale of equity investment	$	—	$	36,179
Cancellation of restricted stock awards	$	334	$	—
Deferred tax liability adjustment to goodwill	$	1,786	$	—
Deferred tax liability adjustment related to warrant exercises	$	—	$	473

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands):


		December 31,					September 30,
		2019		2018			2021		2020
Cash and cash equivalents	Cash and cash equivalents	$	103,189	$	106,892	Cash and cash equivalents	$	204,768	$	166,082
Restricted cash – current		75		0
Restricted cash – non-current		746		745

Restricted cash – noncurrent						Restricted cash – noncurrent	—		746
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	104,010	$	107,637	Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	204,768	$	166,828

September 30,
2020 2019
Cash and cash equivalents $ 166,082 $ 230,299
Restricted cash – current 0 20
Restricted cash – non-current 746 746
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 166,828 $ 231,065


	December 31,
	2020		2019
Cash and cash equivalents	$	193,470	$	103,189
Restricted cash – current	500		746
Restricted cash – noncurrent	—		75
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	193,970	$	104,010

The accompanying notes are an integral part of these unaudited consolidated financial statements.

1112

~~Table of Contents~~

APOLLO MEDICAL HOLDINGS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Description of Business

Overview

Apollo Medical Holdings, Inc. ~~("ApolloMed") together with its affiliated physician groups and consolidated entities (collectively, the “Company”~~(“ApolloMed”) is a leading physician-centric, ~~technology-enabled~~technology-powered, risk-bearing healthcare ~~management~~ company. Leveraging its proprietary ~~population health management and healthcare delivery platform,~~end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based ~~healthcare model, which aims to empower the providers in its network~~care arrangements, thus empowering them to deliver ~~the highest quality of~~high-quality care to ~~its~~ patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (“NMM”) in December 2017 (the “2017 Merger”). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the “Company,” “we,” “us,” “our,” and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).

Headquartered in Alhambra, California, ~~ApolloMed's~~ApolloMed’s subsidiaries and VIEs include management services organizations ~~("MSOs"~~(“MSOs”), affiliated independent practice associations ~~("IPAs"~~(“IPAs”), and a Next Generation Accountable Care Organization ~~("NGACO"~~(“NGACO”). ~~Network Medical Management, Inc. ("NMM")~~NMM and Apollo Medical Management, Inc. ~~("AMM"~~(“AMM”) are the administrative and managerial services companies for the affiliated ~~physician owned~~physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ~~("APC"~~(“APC”), (ii) Alpha Care Medical Group, Inc. (“Alpha Care”), and (iii) Accountable Health Care IPA, ~~brands.~~a Professional Medical Corporation (“Accountable Health Care”). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ~~("AMH"~~(“AMH”) and Southern California Heart Centers, a Medical Corporation ~~("SCHC"~~(“SCHC”). The ~~Company's~~Company’s NGACO operates under the APA ACO, Inc. ~~("APAACO"~~(“APAACO”) brand and participates in the Centers for Medicare & Medicaid Services (“CMS”) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the ~~program's~~program’s attribution-based ~~risk sharing~~risk-sharing model.

The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, and hospitalists.

MSOs and Affiliates

AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (“AMH”) and Southern California Heart Centers, a Medical Corporation (“SCHC”). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.

NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following ~~a business combination,~~the 2017 Merger, NMM became a ~~wholly-owned~~wholly owned subsidiary of ~~ApolloMed in December 2017.~~ApolloMed.

IPAs and Affiliates

APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC ~~has~~is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (“HMOs”) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is ~~also minimized by~~subject to stop-loss provisions in contracts with HMOs.

In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a ~~variable interest entity (“VIE”)~~VIE of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation on the APC Joint Planning Board; therefore APCand is consolidated by NMM.

AP-AMH Medical Corporation (“AP-AMH”) and AP-AMH 2 Medical Corporation (“AP-AMH 2”) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of ~~AP-AMH. ApolloMed makes all the decisions on behalf of~~ AP-AMH and ~~funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of~~AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and ~~has the option, but not the obligation,~~AP-AMH 2 is determined to ~~cover losses. Therefore, AP-AMH~~be a VIE of ApolloMed and is ~~controlled and~~ consolidated by ~~ApolloMed as the primary beneficiary of this VIE.~~ApolloMed.

In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and ~~APC;~~

~~Table of Contents~~

APC:

1.ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the “AP-AMH Loan”). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH’s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.

2.AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the “Certificate of Determination”), AP-AMH is entitled to receive preferential, cumulative dividends (“Series A Dividends”) that accrue on a daily basis and that are equal to the sum of (i) APC’s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC’s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).

3.APC purchased 15,015,015 shares of ApolloMed’s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed’s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed’s then outstanding shares will be voted by proxy given to ApolloMed’s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed’s stockholders.

4.ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.

5.Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.

As part of the series of ~~transaction,~~transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term ~~excluded assets ("Excluded Assets").~~“Excluded Assets.” Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of ~~the Company~~APC that are not Healthcare Services Assets (as defined in the purchase agreement), including ~~the Company’s~~APC’s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii).

~~APC's~~APC’s ownership in ApolloMed was ~~32.00% at~~19.77% as of September 30, ~~2020~~2021 and ~~32.50% at~~22.58% as of December 31, ~~2019.~~2020.

Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is ~~Medicare certified~~Medicare-certified and accredited by the Accreditation Association for Ambulatory ~~Healthcare, Inc.~~Healthcare. As of September 30, ~~2020,~~2021, APC owned 45.01% of CDSC’s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE ~~and~~of APC ~~is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC’s economic performance~~ and ~~receives the most economic benefits; therefore CDSC~~ is consolidated by APC.

APC-LSMA Designated Shareholder Medical Corporation (“APC-LSMA”) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of ~~APC.~~APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC

has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group of Southern California (“DMG”), and AHMC International Cancer Center, a Medical Corporation (“ICC”). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group,

~~Table of Contents~~

Inc. (“MMG”), Alpha Care, ~~Medical Group, Inc. (“Alpha Care”),~~ Accountable Health Care, ~~IPA, a Professional Medical Corporation (“Accountable Health Care”),~~ and AMG, a Professional Medical Corporation (“AMG”).

Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a ~~risk bearing~~risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.

Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care ~~currently has a network of over 300 primary care physicians and 600 specialty care physicians, as well as 1 community and regional hospital medical center, that~~ provides quality healthcare services to its members ofthrough 3 federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, ~~Medicare~~ and ~~the California Healthy Families program.~~Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care’s capital stock that they did not already own (comprising 75%) for $7.3 million in ~~cash (see Note 3).~~cash.

AMG is a network of family practice clinics operating out of 3 main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common ~~stock (see Note 3).~~stock.

~~Universal Care Acquisition~~In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (“~~UCAP”~~MPP”), AMG Properties, LLC (“AMG Properties”), and ZLL Partners, LLC (“ZLL”) and a 50% interest in each of One MSO, LLC (“One MSO”), Tag-6 Medical Investment Group, LLC (“Tag 6”), and Tag-8 Medical Investment Group, LLC (“Tag 8”). These entities own buildings that are currently leased to tenants as well as vacant land which they plan to develop in the future. MPP, AMG Properties, and ZLL are 100% owned ~~subsidiary~~subsidiaries of APC ~~was formed~~and are included in ~~June 2014, for~~ the ~~purpose~~consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of holding an investment in Universal Care, Inc. (“UCI”). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 millionTag 8. Based on the ~~date of sale. In addition, pursuant~~reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the ~~terms~~operations of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was $15.7 million (see Note 5). As set forth in the Company’s definitive proxy statement filed with the SEC on July 31, 2019 (the “Proxy Statement”), the 48.9% interest in UCI is included inentity. These purchases are deemed Excluded Assets that ~~remain~~are solely for the benefit of APC and its shareholders. As such, any ~~proceeds or gain on the sale of~~income pertaining to APC’s ~~indirect ownership interest~~interests in ~~UCI~~these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, ~~as described in the Proxy Statement~~ and consequently ~~the sale did~~will not affect net income attributable to ApolloMed.

In July 2021, AP-AMH 2 Medical Corporation (“AP-AMH 2”), a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (“APCMG”), a primary care physicians’ group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company (see Note 3).

In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (“Sun Labs”) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of at $4.2 million at September 30, 2021. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.

NGACO

APAACO, jointly owned by NMM and AMM, began participating in the ~~Next Generation Accountable Care Organization (“NGACO")~~NGACO Model of ~~the Centers for Medicare & Medicaid Services (“CMS”)~~CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based ~~risk sharing~~risk-sharing model.

AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (“AMH”) and Southern California Heart Centers, a Medical Corporation (“SCHC”). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated balance ~~sheet~~sheets at December 31, ~~2019, has~~2020, have been derived from the Company’s audited consolidated financial statements, but ~~does~~do not include all annual disclosures required by generally accepted accounting principles in the United States of America (“U.S. GAAP”). The accompanying unaudited consolidated financial statements as of September 30, ~~2020,~~2021, and for the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, have been prepared in accordance with U.S. GAAP for interim financial ~~information~~statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, ~~they do not include all of the information and footnotes required by U.S. GAAP for complete~~these unaudited consolidated financial statements ~~and~~ should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020, as filed with the ~~SEC~~Securities and Exchange Commission (“SEC”) on March ~~16, 2020.~~15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as

~~Table of Contents~~

required by Regulation S-X, Rule 10-01. Operating results for the three and nine months ended September 30, ~~2020,~~2021, are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2020,~~2021, or any future periods.

Principles of Consolidation

The consolidated balance sheets as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, and the consolidated statements of ~~income~~operations for the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, include the accounts of ~~ApolloMed,~~ApolloMed; its consolidated subsidiaries, NMM, AMM, and ~~APAACO,~~APAACO; its consolidated VIEs, AP-AMH, AP-AMH 2, and Sun Labs; AP-AMH 2’s consolidated subsidiary, APCMG; AMM’s consolidated VIE, ~~AP-AMH, NMM's~~SCHC; NMM’s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM’s consolidated VIE, ~~APC,~~APC; APC’s ~~subsidiary, UCAP,~~consolidated subsidiaries, Universal Care Acquisition Partners, LLC (“UCAP”), MPP, AMG Properties and ZLL, APC’s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA’s consolidated subsidiaries, Alpha Care, ~~and~~ Accountable Health ~~Care.~~

~~All material intercompany balances~~Care, and ~~transactions have been eliminated in consolidation.~~

AMG.

Use of Estimates

The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, ~~and~~ completion factors ~~including~~and historical ~~medical loss ratios (“MLR”))~~margins), income ~~taxes, valuation of~~tax-valuation allowance, share-based compensation, and right-of-use ~~("ROU")~~ assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.

Variable Interest Entities

On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:

•The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and

•The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets.

If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.

A legal entity is determined to be a VIE if it has any of the following three characteristics:

1.The entity does not have sufficient equity to finance its activities without additional subordinated financial support;

2.The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or

3.The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:

a.The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by:

i.Substantive participating rights in day-to-day management of the entity’s activities; or

ii.Substantive kick-out rights over the party responsible for significant decisions;

iii.The obligation to absorb the entity’s expected losses; or

iv.The right to receive the entity’s expected residual returns.

If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.

Variable interest model

If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.

Business Combinations

The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.

Reportable Segments

The Company operates as 1 reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in 1 reportable segment.

Cash and Cash Equivalents

The Company’s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.

The Company maintains its cash in deposit accounts with several banks, which at times may exceed the insured limits of the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of September 30, 2021 and December 31, 2020, the Company’s deposit accounts with banks exceeded the FDIC’s insured limit by approximately ~~$321.2~~$301.7 million ~~including approximately $118.3~~and $294.9 million, ~~in certificates of deposit that were recognized as investments in marketable securities.~~respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company’s concentration of risk exposure.

Restricted Cash

Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.

Investments in Marketable Securities

Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of September 30, 2020 and December 31, 2019, investments in marketable securities amounted to approximately $118.3 million and $116.5 million, respectively, and consisted of equity securities and certificates

Certificates of deposit ~~with various financial institutions,~~are reported at par value, plus accrued interest, with maturity dates from four months to 24 ~~months (see fair value measurements~~months. As of ~~financial instruments below).~~September 30, 2021 and December 31, 2020, certificates of deposit amounted to approximately $67.5 million and $67.6 million, respectively. Investments in certificates of ~~deposits~~deposit are classified as Level 1 investments in the fair value hierarchy.

~~Table~~Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of ~~Contents~~certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.

Equity securities held by the Company are comprised of common stock of a payor partner that completed its initial public offering(“IPO”) in June 2021 and Clinigence Holdings, Inc. (“Clinigence”). The shares were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (“UCI”) in April 2020. As of September 30, 2021, the equity securities from the payor partner amounted to $57.0 million. As of December 31, 2020, prior to our payor partner’s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0 million. The common stock is included in investments in marketable securities.

For the three and nine months ended September 30, 2021, the Company recognized unrealized losses of $62.0 million and unrealized gains of $21.8 million on all equity securities in unrealized gain or loss on investments in the accompanying consolidated statements of operations.

Receivables, ~~and~~ Receivables – Related Parties, and Loan Receivable - Related Party

The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, ~~and~~ incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.

The Company’s receivables – related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables – related parties are recorded and stated at the amount expected to be collected.

The Company’s loan receivable – related party consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum.

Capitation and claims ~~receivable~~receivables relate to each health plan’s capitation and isare received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company’s full risk pool receivable that is recorded quarterly based on reports received from the Company’s hospital partners and management’s estimate of the Company’s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables ~~consists~~consist of recoverable claims paid related to the ~~2019~~2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and ~~stop loss~~stop-loss insurance premium reimbursements.

The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.

Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses ~~(CECL)~~(“CECL”) model. ~~As of September 30, 2020 and December 31, 2019, the Company had $1.3 million and $2.9 million of allowance for doubtful accounts, respectively.~~

Concentrations of Credit Risks

The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of ~~income~~operations present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and nine months ended September 30, ~~2020~~2021 and ~~2019~~2020 (in thousands):

Three Months Ended September 30,
2020 2019
Commercial $ 25,041 $ 25,429
Medicare 79,649 60,737
Medicaid 65,849 61,189
Other third parties 9,584 8,705
Revenue $ 180,123 $ 156,060

~~Table of Contents~~


		Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019			2021		2020		2021		2020

Commercial	Commercial	$	75,233	$	75,883	Commercial	$	36,960	$	25,041	$	102,522	$	75,233
Medicare	Medicare	206,567		155,730		Medicare	103,919		79,649		232,869		206,567
Medicaid	Medicaid	200,746		122,837		Medicaid	74,262		65,849		212,408		200,746
Other third parties	Other third parties	27,851		27,417		Other third parties	11,976		9,584		31,016		27,851
Revenue	Revenue	$	510,397	$	381,867	Revenue	$	227,117	$	180,123	$	578,815	$	510,397

The Company had major payors that contributed the following percentages of net revenue:

Three Months Ended
September 30,
2020 2019
Payor A 12.7 % 12.0 %
Payor B * 11.7 %
Payor D 16.2 % 12.0 %
Payor E 16.7 % 19.9 %


		Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019			2021		2020		2021		2020

Payor A	Payor A	12.1	%	14.3	%	Payor A	13.8	%	12.7	%	13.1	%	12.1	%
Payor B	Payor B	10.1	%	13.3	%	Payor B	*		*		10.1	%	10.1	%
Payor C	Payor C	*		10.0	%	Payor C	13.3	%	16.2	%	15.4	%	17.0	%
Payor D	Payor D	17.0	%	*		Payor D	17.1	%	16.7	%	12.1	%	14.2	%
Payor E		14.2	%	11.0	%

* Less than 10% of total net revenues

The Company had major payors that contributed to the following percentages of receivables and receivables – related parties:


		As of September 30, 2020		As of December 31, 2019			As of September 30, 2021		As of December 31, 2020

Payor D		16.7	%	*

Payor C						Payor C	13.7	%	*
Payor F	Payor F	32.5	%	30.4	%	Payor F	42.0	%	43.9	%
Payor G	Payor G	29.2	%	36.0	%	Payor G	25.8	%	36.5	%

* Less than 10% of total receivables and receivables — related parties, net

Fair Value Measurements of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.

1719

~~Table of Contents~~

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.

This hierarchy prioritizes the inputs into three broad levels as follows:

Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.

Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 — Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company’s own data.

The carrying amounts and fair values of the Company’s financial instruments as of September 30, ~~2020,~~2021, are presented below (in thousands):


		Fair Value Measurements									Fair Value Measurements
		Level 1		Level 2		Level 3		Total			Level 1		Level 2		Level 3		Total
Assets	Assets									Assets
Money market funds*	Money market funds*	$	115,039	$	0	$	0	$	115,039	Money market funds*	$	89,678	$	—	$	—	$	89,678
Marketable securities – certificates of deposit	Marketable securities – certificates of deposit	118,262		0		0		118,262		Marketable securities – certificates of deposit	67,540		—		—		67,540
Marketable securities – equity securities	Marketable securities – equity securities	47		0		0		47		Marketable securities – equity securities	57,108		3,910		—		61,018
Warrants										Warrants	—		1,045		—		1,045
Total assets										Total assets	$	214,326	$	4,955	$	—	$	219,281

Total		$	233,348	$	0	$	0	$	233,348
Liabilities										Liabilities
Interest rate swaps										Interest rate swaps	$	—	$	1,010	$	—	$	1,010
APCMG contingent consideration										APCMG contingent consideration	—		—		1,000		1,000
Total liabilities										Total liabilities	$	—	$	1,010	$	1,000	$	2,010

* Included in cash and cash equivalents

The carrying amounts and fair values of the Company’s financial instruments as of December 31, ~~2019,~~2020, are presented below (in thousands):


		Fair Value Measurements									Fair Value Measurements
		Level 1		Level 2		Level 3		Total			Level 1		Level 2		Level 3		Total
Assets	Assets									Assets
Money market funds*	Money market funds*	$	50,731	$	0	$	0	$	50,731	Money market funds*	$	115,769	$	—	$	—	$	115,769
Marketable securities – certificates of deposit	Marketable securities – certificates of deposit	116,469		0		0		116,469		Marketable securities – certificates of deposit	67,637		—		—		67,637
Marketable securities – equity securities	Marketable securities – equity securities	70		0		0		70		Marketable securities – equity securities	58		—		—		58

Total	Total	$	167,270	$	0	$	0	$	167,270	Total	$	183,464	$	—	$	—	$	183,464

* Included in cash and cash equivalents

There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September 30, ~~2020.~~2021.

Intangible Assets and Long-Lived Assets

Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.

Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.

~~Table of Contents~~

Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was 0no impairment of its finite-lived intangible or long-lived assets during the nine months ended September 30, ~~2020~~2021 and ~~2019.~~2020.

Goodwill and Indefinite-Lived Intangible Assets

Under ASC 350, Intangibles – Goodwill and Other, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.

At least annually, at the Company’s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company’s 3 ~~main~~ reporting units (1) management services, (2) IPAs, and (3) ~~ACOs.~~accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit’s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.

An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.

At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.

The Company had 0no impairment of its goodwill or indefinite-lived intangible assets during the ~~three and~~ nine months ended September 30, ~~2020. However, during the three~~2021 and nine months ended September 30, 2019, the Company recorded impairment of indefinite-lived intangible assets of $2.0 million related to Medicare licenses it acquired as part of the 2017 merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom.2020.

Investments in Other Entities — Equity Method

The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company’s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of ~~income~~operations under ~~“Income~~income (loss) from equity method ~~investments”~~investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation.

Investments in Privately Held Entities

The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The

investments in privately held entities that do not report ~~NAV~~net asset value are subject to qualitative assessment for indicators of impairments.

Medical Liabilities

APC, Alpha Care, Accountable Health Care, ~~APAACO~~ and ~~MMG~~APCMG (“consolidated IPAs”) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. ~~APC, Alpha Care, Accountable Health Care,~~These IPAs and APAACO ~~and MMG~~ provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of ~~income.~~

~~Table of Contents~~

operations.

An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and ~~estimates~~estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation.

Fiduciary Cash and Payable

The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $8.8 million and $9.6 million as of September 30, 2021 and December 31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.

Derivative Financial Instruments

Interest Rate Swap Agreements

The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company’s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of operations.

The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of September 30, 2021, was $1.0 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.

Warrants

In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0 million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of operations. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of September 30, 2021 was $1.0 million and is presented within other assets in the accompanying consolidated balance sheets.

Revenue Recognition

The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.

Nature of Services and Revenue Streams

Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (“AIPBP”), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may vary by type of revenue and the customer. The following is a summary of the principal forms of the Company’s billing arrangements and how revenue is recognized for each.

Capitation, Net

Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a “Risk Adjustment” model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.

PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk ~~shares.~~sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company’s net PMPM transaction price relates specifically to the Company’s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.

Risk Pool Settlements and Incentives

~~Table of Contents~~

APC enters into ~~full risk~~full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a ~~full risk~~full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated ~~hospitals~~hospital’s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company’s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical ~~MLR,~~margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.

Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees ~~(shared risk arrangements)~~ and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk ~~capitation~~ arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the ~~extent of any)~~extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.

The Company’s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans’ data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC’s risk share revenue is deemed to be fully constrained until APC is notified of the

amount by the health plan. ~~Risk~~Final settlement of risk pools for ~~the~~ prior contract years ~~are~~ generally ~~final settled~~occur in the third or fourth quarter of the following year.

In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company’s incentives under “pay-for-performance” programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.

Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day’s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.

NGACO AIPBP Revenue

~~APAACO and CMS entered into a NGACO Model Participation Agreement (the “Participation Agreement”) with an initial term of~~ ~~two~~ ~~performance years through December 31, 2018, which term was extended for~~ ~~two~~ ~~additional renewal years.~~

For each performance year, the Company must submit to CMS its selections for risk ~~arrangement;~~arrangement, the amount of the profit/loss ~~cap;~~cap, alternative payment ~~mechanism;~~mechanism, benefits enhancements, if ~~any;~~any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.

Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives ~~capitation~~capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such ~~capitation~~AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, ~~and the~~

~~Table of Contents~~

while claims from APAACO’s in-network contracted providers are paid by APAACO. The Company’s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company’s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company’s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company’s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO ~~capitation~~AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 8), ~~and monthly capitation received~~ are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess ~~capitation paid~~AIPBPs for the performance year and the excess is refunded to CMS.

For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the ~~Company;~~Company, the risk arrangement for which the Company has been approved by ~~CMS;~~CMS, and as otherwise provided in ~~the~~an NGACO Participation ~~Agreement.~~Agreement between APAACO and CMS (the “Participation Agreement”). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.

The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO’s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.

As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company ~~received $19.8~~recognized $21.8 million ~~in risk pool savings~~ related to savings from the ~~2019~~2020 performance ~~year,~~years. The settlement was finalized in October 2021 and ~~has recognized such amount~~recorded as revenue in ~~the~~ risk pool settlements and incentives ~~line of~~in the accompanying consolidated statements of ~~income~~operations for the three and nine months ended September 30, ~~2020.~~2021.

For performance year ~~2020,~~2021, the Company ~~continues to receive~~receives monthly AIPBP payments at a rate of approximately ~~$7.6~~$8.0 million per month from CMS, and ~~will need to continue to~~must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately ~~$22.9~~$23.9 million and ~~$68.4~~$72.0 million in total AIPBP payments for the three and nine months ended September 30, ~~2020,~~2021, respectively, of which ~~$14.8~~$17.6 million and ~~$57.3~~$48.9 million has been recognized as revenue for the three months and nine months ended September 30, ~~2020,~~2021, respectively.

Management Fee Income

Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.

The Company provides a significant service of integrating the services selected by the Company’s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company’s performance obligation is to stand ready to provide services over the contractual period. Also, the Company’s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company’s performance obligation is satisfied as the Company completes each period’s obligations.

~~Table of Contents~~

Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company’s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company’s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.

The Company’s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.

Fee-for-Service Revenue

FFS revenue represents revenue earned under contracts in which the ~~Company bills and collects the~~ professional component of charges for medical services rendered by the Company’s ~~contracted physicians~~affiliated physician-owned medical groups are billed and ~~employed physicians. Under the FFS arrangements, the Company bills the~~collected from third-party payors, hospitals, and ~~third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment.~~patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and ~~are~~is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system, and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded

based on the information known at the time of entering of such information into the Company’s billing systems, as well as an estimate of the revenue associated with medical services.

The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company’s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.

Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period. Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. ~~Accordingly, there was no change in the Company’s method to recognize revenue under ASC 606~~ ~~Revenue from Contracts with Customers~~ ~~from the previous accounting guidance.~~

Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.

The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether ~~and with whom~~ the patients, ~~the Company provides~~to whom services toare provided, in the period are insured and the ~~Company’s~~ contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of ~~income~~operations in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.

~~Table of Contents~~

Contract Assets

~~Typically, revenues~~Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company’s contract assets are comprised of receivables and receivables – related parties.

The Company’s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable ~~agings~~aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.

Contract Liabilities (Deferred Revenue)

Contract liabilities are recorded when cash payments are received in advance of the Company’s performance, or in the case of the Company’s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company’s contract liability balance was ~~$12.3~~$17.3 million and ~~$8.9~~$13.0 million as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively, and is presented within ~~“Accounts~~accounts payable and accrued ~~expenses”~~expenses in the accompanying consolidated balance sheets. During the nine months ended September 30, ~~2020,~~2021, $0.4 million of the Company’s contract liability accrued in ~~2019~~2020 has been recognized as ~~revenue and $8.5 million was repaid to CMS for AIPBP capitation received and not earned.~~

~~Other Financial Information~~

In March 2020, the Company made a deposit of $4.0 million for future investment opportunities. The deposit was made with cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. The deposit is included in “Other assets” in the accompanying consolidated balance sheets. Subsequent to September 30, 2020, an agreement was signed converting this deposit into a promissory note from a related party (see Note 17).revenue.

Income Taxes

Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.

Share-Based Compensation

The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company’s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.

Basic and Diluted Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to holders of the Company’s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 1415 for a discussion of shares treated as treasury shares for accounting purposes.

~~Table of Contents~~

Noncontrolling Interests

The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company’s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of ~~income.~~operations.

Mezzanine Equity

Pursuant to APC’s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase ~~the~~its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September 30, ~~2020~~2021 and December 31, ~~2019, APC's~~2020, APC’s shares were not redeemable, nor was it probable the shares would become redeemable.

~~Recent Accounting Pronouncements~~

~~In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13,~~ ~~Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments~~ (“ASU 2016-13”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.

~~In October 2018, the FASB issued ASU No. 2018-17,~~ ~~Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities~~ (“ASU 2018-17”). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.

Leases

~~In December 2019, the FASB issued ASU No. 2019-12,~~ ~~Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes~~ ~~(“ASU 2019-12”). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740~~ ~~Income Taxes~~ related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.

~~In January 2020, the FASB issued ASU No. 2020-01,~~ ~~Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)~~ (“ASU 2020-01”). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.

Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company’s financial position, results of operations and cash flows.

~~Table of Contents~~

~~3. Business Combinations and Goodwill~~

~~Alpha Care Medical Group, Inc.~~

On May 31, 2019, APC and APC-LSMA completed their acquisition of 100% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $45.1 million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $2.0 million into an escrow account for potential post-closing adjustments. As of September 30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets.

~~The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):~~


	~~Balance Sheet~~
~~Assets acquired~~
~~Cash and cash equivalents~~	$	~~3,569~~
~~Accounts receivable, net~~	~~10,336~~
~~Other current assets~~	~~4,675~~
~~Network relationship intangible assets~~	~~22,636~~
~~Goodwill~~	~~28,585~~
~~Accounts payable~~	~~(2,795)~~
~~Deferred tax liabilities~~	~~(6,334)~~
~~Medical liabilities~~	~~(15,616)~~
~~Net assets acquired~~	$	~~45,056~~

~~Cash paid~~	$	~~45,056~~

~~Accountable Health Care, IPA, a Professional Medical Corporation~~

On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising 75%) in Accountable Health Care in exchange for $7.3 million. In addition to the payment of $7.3 million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $15.4 million, which have been eliminated upon consolidation and contributed the 25% investment totaling $2.4 million, total purchase price was $25.1 million (see Note 5).

~~The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):~~


	~~Balance Sheet~~
~~Assets acquired~~
~~Cash and cash equivalents~~	$	~~582~~
~~Accounts receivable, net~~	~~5,150~~
~~Other current assets~~	~~198~~
~~Network relationship intangible assets~~	~~11,411~~
~~Goodwill~~	~~23,566~~
~~Accounts payable~~	~~(3,759)~~
~~Medical liabilities~~	~~(12,154)~~
~~Subordinated loan~~	~~(15,327)~~
~~Net asset acquired~~	$	~~9,667~~

~~Equity investment contributed~~	$	~~2,417~~
~~Cash paid~~	$	~~7,250~~

~~Table of Contents~~

~~AMG, a Professional Medical Corporation~~

The Company ~~acquired AMG in September 2019,~~determines if an arrangement is a lease at its inception. The expected term of the lease used for ~~total consideration~~computing the lease liability and right-of-use asset and determining the classification of ~~$1.6 million,~~the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of ~~which $0.4 million was in~~ the ~~form~~following: (1) the election for classes of ~~APC common stock.~~underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The ~~business combination did not meet the quantitative thresholds to require separate disclosures based on the Company’s consolidated net assets, investments and net income.~~

~~The acquisitions were accounted for under the acquisition method of accounting. The fair~~present value of the ~~consideration for~~lease payments is calculated using a rate implicit in the ~~acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess~~lease, when readily determinable. However, as most of the ~~purchase consideration over~~Company’s leases do not provide an implicit rate, the ~~fair~~Company uses its incremental borrowing rate to determine the present value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company acquired have been included in the Company’s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.

At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.

~~Goodwill is not deductible for tax purposes.~~

~~The change in the carrying value of goodwill~~lease payments for the ~~nine months ended September 30, 2020, was as follows (in thousands);~~


~~Balance, January 1, 2020~~	$	~~238,505~~
~~Adjustments~~	~~548~~

~~Balance, September 30, 2020~~	$	~~239,053~~

majority of its leases.

~~Table of Contents~~

~~4. Intangible Assets, Net~~

~~At September 30, 2020, the Company’s intangible assets, net, consisted of the following (in thousands):~~

Useful
Life
(Years)
Gross September 30,
2020 Accumulated
Amortization Net September 30,
2020
Amortized intangible assets:
Network relationships 11-15 $ 143,930 $ (70,200) $ 73,730
Management contracts 15 22,832 (11,225) 11,607
Member relationships 12 6,696 (3,013) 3,683
Patient management platform 5 2,060 (1,167) 893
Trade names/trademarks 20 1,011 (143) 868
$ 176,529 $ (85,748) $ 90,781

~~At December 31, 2019, the Company’s intangible assets, net, consisted of the following (in thousands):~~

Useful
Life
(Years)
Gross December 31,
2019 Accumulated
Amortization Net December 31, 2019
Amortized intangible assets:
Network relationships 11-15 $ 143,930 $ (60,526) $ 83,404
Management contracts 15 22,832 (9,676) 13,156
Member relationships 12 6,696 (2,352) 4,344
Patient management platform 5 2,060 (858) 1,202
Trade names/trademarks 20 1,011 (105) 906
$ 176,529 $ (73,517) $ 103,012

Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $4.0 million and $4.3 million for the three months ended September 30, 2020 and 2019, respectively, and $12.3 million and $12.1 million for the nine months ended September 30, 2020 and 2019, respectively.

~~Future amortization expense is estimated to be as follows for the following years ending December 31 (in thousands):~~

Amount
2020 (excluding the nine months ended September 30, 2020) $ 3,798
2021 14,524
2022 12,673
2023 10,842
2024 9,830
Thereafter 39,114
Total $ 90,781

~~Table of Contents~~

Beneficial Interest

~~5. Investments in Other Entities — Equity Method~~

~~Rollforward of Equity Method Investment (in thousands)~~

December 31,
2019 Allocation of Income (Loss) Contribution Sale September 30,
2020
LaSalle Medical Associates – IPA Line of Business $ 6,397 $ 28 $ 0 $ — $ 6,425
Pacific Medical Imaging & Oncology Center, Inc. 1,396 25 0 — 1,421
Universal Care, Inc. 1,438 3,560 0 (4,998) 0
Diagnostic Medical Group 2,334 19 0 — 2,353
531 W. College, LLC – related party 16,698 (351) 500 — 16,847
MWN, LLC – related party 164 10 0 — 174
$ 28,427 $ 3,291 $ 500 $ (4,998) $ 27,220

~~LaSalle Medical Associates —~~ ~~IPA Line of Business~~

LMA was founded by Dr. Albert Arteaga in 1996 and currently operates 6 neighborhood medical centers through its network of approximately 2,300 PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA’s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately 290,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered intoIn April 2020, when UCAP, a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA’s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA’s operations. For the three months ended September 30, 2020, APC recognized income from this investment of $0.5 million. For the three months ended September 30, 2019, APC recognized a loss from this investment of $0.4 million. For the nine months ended September 30, 2020, APC recognized income from this investment of $28,000 in the accompanying consolidated statements of income. For the nine months ended September 30, 2019, APC recognized a loss from this investment of $2.8 million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $6.4 million at September 30, 2020 and December 31, 2019, respectively.

~~Table of Contents~~

LMA’s summarized balance sheets at September 30, 2020 and December 31, 2019, and summarized statements of operations for the nine months ended September 30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):

~~Balance Sheets~~

September 30,
2020 December 31,
2019
Assets
Cash and cash equivalents $ 3,794 $ 6,345
Receivables, net 6,782 5,124
Other current assets 880 3,526
Loan receivable 2,250 2,250
Restricted cash 690 683
Total assets $ 14,396 $ 17,928
Liabilities and Stockholders’ Deficit
Current liabilities $ 19,886 $ 23,530
Stockholders’ deficit (5,490) (5,602)
Total liabilities and stockholders’ deficit $ 14,396 $ 17,928

~~Statements of Operations~~

Nine Months Ended September 30,
2020 2019
Revenues $ 138,490 $ 144,570
Expenses 138,233 155,582
Net income (loss) $ 257 $ (11,012)

~~Pacific Medical Imaging and Oncology Center, Inc.~~

Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.

~~In July 2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.~~

~~APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf~~100% owned subsidiary of APC, to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.5 million and $0.7 million, for the three months ended September 30, 2020 and 2019, respectively, and fees of approximately $1.5 million and $2.1 million for the nine months ended September 30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC’s operations. For the three months ended September 30, 2020, APC recognized a loss from this investment of $52,000. For the three months ended September 30, 2019, APC recognized income from this investment of $31,000. For the nine months ended September 30, 2020 and 2019, APC recognized income of $25,000 and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $1.4 million at September 30, 2020 and December 31, 2019, respectively.

~~Table of Contents~~

~~Universal Care, Inc.~~

UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.

In August 2015, UCAP purchased 100,000 shares of UCI class A-2 voting common stock from UCI for $10.0 million, which shares comprise 48.9% of UCI’s total outstanding shares and 50% of UCI’s voting common stock.

~~On April 30, 2020, UCAP completed the sale of~~sold its 48.9% ownership interest in UCI, ~~to Bright for approximately $69.2 million~~APC received a beneficial interest in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.’s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition,equity method investment sold, pursuant to the terms of the stock purchase ~~agreement, APC has a beneficial interest in the equity method investment sold.~~agreement. The estimated fair value of such interest onin April ~~30,~~ 2020, was $15.7 million and is included in ~~"Other assets"~~other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6 million and preferred shares with an estimated fair value of $6.4 million, total estimated fair value of $22.0 million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a ~~probability weighted~~probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific ~~collar~~dollar amount. In June 2021, UCI’s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7 million was written off and expensed in other income in the accompanying consolidated statements of operations for the nine months ended September 30, 2021.

Recent Accounting Pronouncements

In December 2019, the FASB issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 Income Taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.

Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company’s financial position, results of operations and cash flows.

3. Business Combinations and Goodwill

APCMG

On July 31, 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG’s financial performance for fiscal year 2022. The contingent consideration is met if gross revenue and EBITDA targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of September 30, 2021, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.

Sun Labs

On August 1, 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the noncontrolling interest, the noncontrolling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.

The ~~gain~~acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG and Sun Labs have been included in the Company’s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.

At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on ~~sale~~a valuation and the facts and circumstances available at the time. The Company determines the final value of ~~equity method investment recognized~~the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.

Goodwill is not deductible for tax purposes.

The change in ~~connection with this transaction~~the carrying value of goodwill for the nine months ended September 30, 2021 was ~~determined~~ as follows (in thousands):;


	~~Amount~~

~~Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)~~Balance, January 1, 2021	$	~~52,743~~239,053
~~Preferred shares in Bright Health, Inc.~~Acquisitions	~~36,179~~4,300
~~Beneficial interest in UCI~~Balance, September 30, 2021	~~15,723~~
~~Less: Carrying value of equity method investment on date of sale~~$	~~(4,998)~~243,353

~~Gain on sale of equity method investment~~	$	~~99,647~~

4. Intangible Assets, Net

At September 30, 2021, the Company’s intangible assets, net, consisted of the following (in thousands):


	Useful Life (Years)	Gross September 30, 2021		Accumulated Amortization		Net September 30, 2021
Indefinite lived assets:
Trademarks	N/A	$	996	$	—	$	996
Amortized intangible assets:
Network relationships	11-15	$	148,845	$	(82,117)	$	66,728
Management contracts	15	22,832		(13,128)		9,704
Member relationships	12	8,997		(4,129)		4,868
Patient management platform	5	2,060		(1,579)		481
Trade names/trademarks	20	1,011		(194)		817
		$	184,741	$	(101,147)	$	83,594

At December 31, 2020, the Company’s intangible assets, net, consisted of the following (in thousands):


	Useful Life (Years)	Gross December 31, 2020		Accumulated Amortization		Net December 31, 2020
Amortized intangible assets:
Network relationships	11-15	$	143,930	$	(73,169)	$	70,761
Management contracts	15	22,832		(11,715)		11,117
Member relationships	12	6,696		(3,234)		3,462
Patient management platform	5	2,060		(1,270)		790
Trade names/trademarks	20	1,011		(156)		855
		$	176,529	$	(89,544)	$	86,985

Included in depreciation and amortization on the accompanying consolidated statements of operations is amortization expense of $4.1 million and $4.0 million for the three months ended September 30, 2021 and 2020, respectively, and $11.6 million and $12.3 million for the nine months ended September 30, 2021 and 2020, respectively.

Future amortization expense is estimated to be as follows for the following years ending December 31 (in thousands):


	Amount

2021 (excluding the nine months ended September 30, 2021)	$	4,007
2022	13,962
2023	11,767
2024	10,584
2025	9,370
Thereafter	32,908

Total	$	82,598

5. Investments in Other Entities — Equity Method

Rollforward of Equity Method Investment (in thousands)


	December 31, 2020		Initial Investment		Allocation of Income (Loss)		Contribution		Entity Consolidated		Sale		September 30, 2021
LaSalle Medical Associates – IPA Line of Business	$	13,047	$	—	$	(4,654)	$	—	$	—	$	(4,182)	$	4,211
Pacific Medical Imaging & Oncology Center, Inc.	1,413		—		129		—		—		—		1,542
Diagnostic Medical Group	2,613		—		330		—		—		—		2,943
531 W. College, LLC – related party	17,200		—		(149)		—		—		—		17,051
One MSO, LLC – related party	2,395		—		379		—		—		—		2,774
Tag-6 Medical Investment Group, LLC – related party	4,516		—		240		—		—		—		4,756
Tag-8 Medical Investment Group, LLC – related party	2,108		—		—		1,660		(3,768)		—		—
CAIPA MSO, LLC	—		11,724		45		—		—		—		11,769
	$	43,292	$	11,724	$	(3,680)	$	1,660	$	(3,768)	$	(4,182)	$	45,046

LaSalle Medical Associates — IPA Line of Business

LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA’s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA’s IPA line of business. In December 2020, the Company exercised its option to convert the promissory note totaling $6.4 million due from Dr. Arteaga into an additional 21.25% interest in LMA’s IPA line of business. As a result, APC-LSMA’s interest in LMA’s IPA line of business increased to 46.25%. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in APC-LSMA owning a 25% interest in LMA as of September 30, 2021.

APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA’s operations. For the three months ended September 30, ~~2019~~2021 and 2020, APC ~~recorded income~~recognized a loss from this investment of ~~approximately $0.6 million. For the nine months ended September 30, 2020 and 2019 APC recorded income from this investment of approximately $3.6~~$0.3 million and ~~$6.2~~income of $0.5 million, respectively, in the accompanying consolidated statements of ~~income. As a result of~~operations. For the ~~sale, there was 0 investment balance as of~~nine months ended September 30, 2021 and September 30, 2020, ~~as compared to an~~APC recognized a loss from this investment of $4.7 million and income of $28,000, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of ~~$1.4~~$4.2 million ~~as of~~and $13.0 million at September 30, 2021 and December 31, ~~2019.~~2020, respectively.

~~Table of Contents~~

~~UCI's~~LMA’s summarized balance ~~sheet~~sheets at September 30, 2021 and December 31, ~~2019~~2020, and summarized statements of ~~income~~operations for the ~~four months ended April 30, 2020 and~~ nine months ended September 30, ~~2019~~2021 and 2020, with respect to its IPA line of business are as follows (in thousands):

Balance Sheets


	December 31, 2019
~~Assets~~

~~Cash and cash equivalents~~	$	~~33,890~~
~~Receivables, net~~	~~63,843~~
~~Other current assets~~	~~38,280~~
~~Loan receivable~~	~~882~~
~~Restricted cash~~	~~4,021~~

~~Total assets~~	$	~~140,916~~

~~Liabilities and Stockholders’ Deficit~~
~~Current liabilities~~	$	~~128,330~~
~~Other liabilities~~	~~33,133~~
~~Stockholders’ deficit~~	~~(20,547)~~

~~Total liabilities and stockholders’ deficit~~	$	~~140,916~~


	September 30, 2021		December 31, 2020
Assets

Cash and cash equivalents	$	2,150	$	9,350
Restricted cash	695		691
Receivables, net	6,178		3,918
Other current assets	—		881
Loan receivable	2,250		2,250

Total assets	$	11,273	$	17,090

Liabilities and Stockholders’ Deficit
Current liabilities	$	27,141	$	21,589
Stockholders’ deficit	(15,868)		(4,499)

Total liabilities and stockholders’ deficit	$	11,273	$	17,090

Statements of Operations

Four Months Ended April 30, 2020 Nine Months Ended September 30, 2019
Revenues $ 195,308 $ 372,181
Expenses 189,028 370,597
Income before benefit from income taxes 6,280 1,584
Benefit from income taxes 0 (11,010)
Net income $ 6,280 $ 12,594


	Nine Months Ended September 30,
	2021		2020

Revenues	$	144,417	$	138,490
Expenses	155,786		138,233

Net (loss) income	$	(11,369)	$	257

Pacific Medical Imaging and Oncology Center, Inc.

In July 2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.

APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.7 million and $0.5 million, for the three months ended September 30, 2021 and 2020, respectively, and fees of approximately $1.7 million and $1.5 million for the nine months ended September 30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC’s operations. For the three months ended September 30, 2021 and 2020, APC recognized a gain from this investment of approximately $0.2 million and a loss from this investment of $52,000, respectively, in the accompanying consolidated statements of operations. For the nine months ended September 30, 2021 and 2020, APC recognized income of $0.1 million and $25,000, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets had investment balances of $1.5 million and $1.4 million at September 30, 2021 and December 31, 2020, respectively.

Diagnostic Medical Group

In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.

APC ~~accounts~~accounted for its investment in DMG under the equity method of accounting as APC ~~has~~had the ability to exercise significant influence, but not control over DMG’s operations.

For the three months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC recognized income from this investment of $0.1 million and ~~$0.3~~$0.1 million, respectively, in the consolidated statements of ~~income.~~operations. For the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC recognized income from this investment of ~~$19,000~~$0.3 million and ~~$0.7 million,~~$19,000, respectively, in the consolidated statements of ~~income.~~operations. The accompanying consolidated balance sheets include the related investment balances of ~~$2.4~~$2.9 million and ~~$2.3~~$2.6 million as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

~~Table of Contents~~

531 W. College LLC – Related Party

In June 2018, College Street Investment LP, a California limited partnership (“CSI”), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each ~~owns~~owned 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.

In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM’s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately ~~$16.8~~$16.1 million.

APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC recognized ~~losses~~a loss from this investment of $34,000 and $0.1 million, ~~respectively.~~respectively, in the accompanying consolidated statements of operations. For the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC recorded ~~losses~~a loss from this investment of ~~$0.4~~$0.1 million and ~~$0.7~~$0.4 million in the accompanying consolidated statements of ~~income,~~operations, respectively. ~~During~~The accompanying consolidated balance sheets include the ~~period ended September 30, 2020, the Company contributed $0.5 million to 531 W. College LLC as part of its 50% interest and had~~related investment balances of ~~$16.8~~$17.1 million and ~~$16.7~~$17.2 million ~~respectively,~~ at September 30, ~~2020~~2021 and December 31, ~~2019.~~2020, respectively.

531 W. College LLC’s balance sheets at September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, and statements of operations for the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, are as follows (in thousands):

Balance sheets


		September 30, 2020		December 31, 2019			September 30, 2021		December 31, 2020
Assets	Assets					Assets

Cash	Cash	$	8	$	139	Cash	$	266	$	648
Other current assets	Other current assets	25		17		Other current assets	25		17
Other assets	Other assets	70		70		Other assets	122		70
Property and equipment, net	Property and equipment, net	33,697		33,581		Property and equipment, net	33,689		33,697

Total assets	Total assets	$	33,800	$	33,807	Total assets	$	34,102	$	34,432

Liabilities and Members’ Equity	Liabilities and Members’ Equity					Liabilities and Members’ Equity

Current liabilities	Current liabilities	$	1,257	$	1,062	Current liabilities	$	—	$	32
Stockholders’ equity	Stockholders’ equity	32,543		32,745		Stockholders’ equity	34,102		34,400

Total liabilities and members’ equity	Total liabilities and members’ equity	$	33,800	$	33,807	Total liabilities and members’ equity	$	34,102	$	34,432

~~Table of Contents~~

Statements of Operation


		Nine Months Ended September 30,					Nine Months Ended September 30,
		2020		2019			2021		2020
Revenues	Revenues	$	0	$	0	Revenues	$	181	$	—
Expenses	Expenses	828		780		Expenses	476		828
Loss from operations	Loss from operations	(828)		(780)		Loss from operations	(295)		(828)

Other income	Other income	32		427		Other income	—		32

Provision for income tax	Provision for income tax	3		0		Provision for income tax	2		3

Net loss	Net loss	$	(799)	$	(353)	Net loss	$	(297)	$	(799)

One MSO, LLC – Related Party

In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (“One MSO”) for $2.4 million. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended September 30, 2021, One MSO recognized income of $0.1 million in the accompanying consolidated statements of operations. For the nine months ended September 30, 2021, One MSO recognized income of $0.4 million in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.4 million at September 30, 2021 and December 31, 2020, respectively.

~~MWN~~Tag-6 Medical Investment Group, LLC –and Tag-8 Medical Investment Group, LLC — Related Party

In December ~~2018, NMM,~~2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in Tag 6 ~~Founders LLC,~~for $4.5 million and a ~~California limited liability company doing business~~50% membership interest in Tag 8 for $2.1 million. The Company reevaluated Tag 8 as ~~Pacific6 Enterprises (“Pacific6”),~~a VIE since APC is a guarantor on the loan agreement between Tag 8 and ~~Health Source MSO Inc.,~~MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a ~~California corporation (“HSMSO”) entered into an operating agreement to govern MWN Community Hospital, LLC~~VIE and is consolidated by the ~~conduct~~Company.

Tag 6 shares common ownership with certain board members of ~~its business~~APC and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own 33.3% of the membership shares based on each member’s initial capital contributions of $3,000 and working capital contributions of $30,000. NMM invested an additional $0.3 million for working capital purposes in August 2019.as such is considered a related party. For the three and nine months ended September 30, 2021, Tag 6 recognized income of $45,000 and $0.2 million, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets include the Tag 6 investment of $4.8 million and $4.5 million at September 30, 2021 and December 31, 2020, ~~NMM recorded loss and income from~~respectively.

CAIPA MSO, LLC

In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (“CAIPA”), a leading independent practice association serving the greater New York City area.

ApolloMed accounts for its investment in ~~MWN LLC~~CAIPA MSO under the equity method of ~~$2,000 and $10,000, respectively.~~accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO’s operations. For the three and nine months ended September 30, ~~2019, NMM recorded loss~~2021, ApolloMed recognized income from ~~its~~ investment ~~in MWN LLC~~ of ~~$0.1 million, respectively,~~$45,000, in the accompanying consolidated statements of ~~income and had an~~operations. The accompanying consolidated balance sheets include the related investment ~~balance~~balances of ~~$0.2~~$11.8 million as of September 30, ~~2020 and December 31, 2019.~~2021.

Investments in privately held entities that do not report net asset value

MediPortal, LLC

In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. ~~Additionally, APC received a~~A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests ~~which MediPortal LLC will grant~~were contingent upon the portal completion date. However, APC ~~upon~~did not exercise the option after completion of ~~its health~~the portal. ~~As of September 30, 2020, the health portal has not been completed.~~ As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.

AchievaMed

OnIn July 1, 2019, NMM and AchievaMed, Inc., a California corporation (“AchievaMed”), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in ~~“Investment~~investments in privately held ~~entities”~~entities in the accompanying consolidated balance sheets as of September 30, ~~2020.~~2021.

~~Bright Health, Inc.~~

In April 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.’s preferred stock having an estimated fair value on the transaction date of approximately $36.2 million. The related investment balance of $36.2 million is included in “Investment in privately held entities” in the accompanying consolidated balance sheet as of September 30, 2020.

~~Table of Contents~~

6. Loan Receivable and Loan Receivable – Related Parties

Loan receivable

~~Dr. Albert Arteaga~~Pacific6

~~On June 28, 2019, APC entered into~~In October 2020, NMM received a ~~convertible secured~~ promissory note ~~with Dr. Albert H. Arteaga, M.D. (“Dr. Arteaga”), Chief Executive Officer~~from Pacific6 totaling $0.5 million as a result of ~~LMA, to loan $6.4 million to Dr. Arteaga.~~the sale of the Company’s interest in MWN. Interest ~~on the loan~~ accrues at a rate ~~that~~of 5% per annum and is ~~equal to the prime rate, plus 1% (4.25% as of September 30, 2020) and~~ payable in monthly ~~installments of interest only on the first day of each month until~~through the maturity date of December ~~31,~~1, 2023.

Loan receivable – related parties

AHMC

In October 2020, ~~at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The~~APC entered into a promissory note ~~is secured by certain shares of LMA common stock held by Dr. Arteaga.~~

~~At any time on or before December 31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding~~with AHMC (the “AHMC Note”) for a principal amount of ~~this note into shares~~$4.0 million with a maturity date of LMA common stock, which equal 21.25% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC’s designee, which may include APC-LSMA. If converted, APC-LSMA and APC’s designee will collectively own 46.25% of the equity of LMA with the remaining 53.75% to be owned by Dr. Arteaga.April 2022. The ~~entire note receivable has been classified under loans receivable~~contractual interest rate on the ~~consolidated balance sheets in the amount of $6.4 million as of September 30, 2020.~~

~~On February 28, 2020, the Company~~AHMC Note is 3.75% per annum. The AHMC Note was entered into ~~an agreement~~using cash strictly related to ~~advance Dr. Arteaga $2.2 million in~~ the ~~ordinary course~~Excluded Assets that were generated from the series of ~~business.~~transactions with AP-AMH. As of September 30, ~~2020~~2021, the ~~advance was fully repaid.~~total principal of $4.0 million remains outstanding. One of the Company’s board members is an officer of AHMC.

The Company assessed the outstanding loan receivable under the CECL model by assessing the ~~party's~~party’s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.

~~Loan receivable~~ – ~~related parties~~

~~Universal Care, Inc.~~

In 2015, APC advanced $5.0 million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $2.5 million, $5.0 million and $4.0 million, respectively. The loans accrue interest at the prime rate, plus 1.00%, or 4.25%, as of March 31, 2020, and 5.75% as of December 31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright.

7. Accounts Payable and Accrued Expenses

The Company’s accounts payable and accrued expenses consisted of the following (in thousands):


		September 30, 2020		December 31, 2019			September 30, 2021		December 31, 2020
Accounts payable	Accounts payable	$	9,569	$	6,914	Accounts payable	$	23,051	$	9,554
Capitation payable	Capitation payable	2,583		2,813		Capitation payable	2,967		3,541
Subcontractor IPA payable	Subcontractor IPA payable	3,413		3,360		Subcontractor IPA payable	2,686		1,662
Professional fees	Professional fees	2,481		1,837		Professional fees	697		1,378
Due to related parties	Due to related parties	0		225		Due to related parties	2,298		50
Contract liabilities						Contract liabilities	17,259		12,988
Accrued compensation	Accrued compensation	10,176		3,238		Accrued compensation	8,547		6,970
Contract liabilities		12,252		8,892

Total accounts payable and accrued expenses	Total accounts payable and accrued expenses	$	40,474	$	27,279	Total accounts payable and accrued expenses	$	57,505	$	36,143

~~Table of Contents~~

8. Medical Liabilities

The Company’s medical liabilities consisted of the following (in thousands):


		September 30, 2020		September 30, 2019			September 30, 2021		September 30, 2020
Medical liabilities, beginning of period	Medical liabilities, beginning of period	$	58,725	$	33,642	Medical liabilities, beginning of period	$	50,330	$	58,725
Acquired (see Note 3)						Acquired (see Note 3)	175		—

Components of medical care costs related to claims incurred:	Components of medical care costs related to claims incurred:					Components of medical care costs related to claims incurred:
Current period	Current period	229,194		175,598		Current period	242,619		229,194
Prior periods	Prior periods	1,731		2,875		Prior periods	(498)		1,731
Total medical care costs	Total medical care costs	230,925		178,473		Total medical care costs	242,121		230,925
Payments for medical care costs related to claims incurred:	Payments for medical care costs related to claims incurred:					Payments for medical care costs related to claims incurred:
Current period	Current period	(178,796)		(135,580)		Current period	(200,582)		(178,796)
Prior periods	Prior periods	(53,231)		(49,164)		Prior periods	(48,948)		(53,231)
Total paid	Total paid	(232,027)		(184,744)		Total paid	(249,530)		(232,027)
Acquired (see Note 3)		0		26,404
Adjustments	Adjustments	(168)		45		Adjustments	(224)		(168)

Medical liabilities, end of period	Medical liabilities, end of period	$	57,455	$	53,820	Medical liabilities, end of period	$	42,872	$	57,455

9. Credit Facility, Bank ~~Loan~~Loans, and Lines of Credit

Credit Facility

The Company’s ~~credit facility consisted~~debt balance consists of the following (in thousands):


	~~September 30, 2020~~

~~Term Loan A~~	$	~~180,500~~
~~Revolver loan~~	~~60,000~~
~~Total debt~~	~~240,500~~

~~Less: Current portion of debt~~	~~(9,500)~~
~~Less: Unamortized financing costs~~	~~(4,949)~~

~~Long-term debt~~	$	~~226,051~~


	September 30, 2021		December 31, 2020

Term Loan A	$	—	$	178,125
Revolver Loan	180,000		60,000
Real Estate Loans	7,447		7,580
Construction Loan	77		—
Total debt	187,524		245,705

Less: Current portion of debt	(207)		(10,889)
Less: Unamortized financing costs	(4,504)		(4,605)

Long-term debt	$	182,813	$	230,211

The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of September 30, 2021 and December 31, 2020, the carrying value was not materially different from fair value, as the interest rates on the Company’s debt approximated rates currently available to the Company.

The following are the future commitments of the Company’s ~~credit facility~~debt for the years ending December 31 (in thousands):


		Amount			Amount
2020 (excluding the nine months ended September 30, 2020)		$	2,375
2021		10,688
2021 (excluding the nine months ended September 30, 2021)				2021 (excluding the nine months ended September 30, 2021)	$	55
2022	2022	14,250		2022	285
2023	2023	15,437		2023	215
2024	2024	197,750		2024	222
2025 and thereafter				2025 and thereafter	186,747

Total	Total	$	240,500	Total	$	187,524

3637

~~Table of Contents~~

Credit Agreement

In September 2019, the Company entered into a secured credit agreement (the “Credit Agreement,” and the credit facility thereunder, the ~~"Credit Facility"~~“Credit Facility”) with Truist Bank ~~(formerly known as~~(f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, ~~(in such capacity, the “Agent”),~~ as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the “Lenders”). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the “Guaranty and Security Agreement”), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement.

lenders. The Credit Agreement ~~provides for~~provided a five-year revolving credit facility to the Company of $100.0 million, ~~(“Revolver Loan”),~~ which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also ~~provides for~~provided a term loan of $190.0 million, (“Term Loan A”). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. ~~The remaining principal payment on the term loan is due on September 11, 2024.~~

The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.

The Company is required to pay an annual facility fee of between 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company’s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc. (now known as Truist Securities Inc.), the lead arranger of the Credit Agreement.

Amounts borrowed under the Credit Agreement ~~will bear~~bore interest at an annual rate equal to either, at the Company’s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (“LIBOR”), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company’s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the agent entered into a Guaranty and Security Agreement (the “Guaranty and Security Agreement”), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan.

On June 16, 2021, the Company entered into an amended and restated credit agreement (the “Amended Credit Agreement” and the credit facility thereunder, the “Amended Credit Facility”) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the “Agent”), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the “Lenders”), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.

The Amended Credit Agreement provides for a five-year revolving credit facility (“Revolver Loan”) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect.

Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company’s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.5%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company’s leverage ratio. As of September 30, ~~2020,~~2021, the interest rate on ~~Term Loan A for the 2020 commitment~~Amended Credit Facility was 1.65%.

The Company is required to pay an annual agent fee of $50,000 and ~~future commitments was 2.72% and 2.77%, respectively. As~~an annual facility fee of ~~September 30, 2020, the interest rate~~0.175% to 0.35% on the ~~Revolver Loan was 2.77%. The base rate is defined in~~available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a ~~manner such that it will not be less than LIBOR.~~quarterly basis based on the Company’s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate ~~of between 2.00% and 3.00%~~equal to 1.25% to 2.5%, as determined on a quarterly basis based on the Company’s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. ~~Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases~~The Company is also required to ~~be reported, the Credit Agreement requires~~pay customary fees between the Company and Truist Bank, the ~~Agent to endeavor to establish a commercially reasonable alternative rate~~lead arranger of ~~interest and until they are able to do so, all borrowings must be at~~ the ~~base rate.~~Amended Credit Agreement.

The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.

~~The~~Amended Credit Agreement requires the Company to comply with 2 key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The ~~maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September 30, 2022. The~~ Company must maintain a minimum consolidated interest coverage ratio of

~~Table of Contents~~

not less than 3.25 to 1.00 as of the last day of each fiscal quarter. ~~As of September 30, 2020, the Company was in compliance with the covenants relating to its credit facility.~~

Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.

The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH’s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company’s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.

In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.

Deferred Financing Costs

In September 2019, the Company recorded deferred financing costs of $6.5 million related to ~~the issuance of~~its entry into the Credit Facility. ~~This amount was~~In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt ~~liability.~~liability using straight-line amortization. The remaining unamortized deferred financing costs ~~will be~~related to the Credit Facility and the new

costs related to the Amended Credit Facility are amortized over the life of the Amended Credit ~~Facility~~Facility. At September 30, 2021 and December 31, 2020, the unamortized deferred financing cost was $4.5 million and $4.6 million, respectively.

Real Estate Loans

On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the ~~effective~~existing loans held by MPP, AMG Properties, and ZLL.

MPP

On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2020, the principal on the loan was $6.4 million with a variable interest rate ~~method.~~of 0.50% less than the independent index, which is the daily Wall Street Journal “Prime Rate.” If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September 30, 2021, the balance outstanding was $6.1 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.

AMG Properties

On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2020, the principal on the loan was $0.7 million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal “Prime Rate.” If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September 30, 2021, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.

ZLL

On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2020, the principal on the loan was $0.7 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal “Prime Rate.” If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of September 30, 2021, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.

Construction Loan

In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (“Construction Loan”). Tag 8 is a VIE consolidated by the Company.

The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (“Construction Loan Term”). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (“Permanent Loan Term”). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of September 30, 2021, the balance outstanding was $0.1 million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8’s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated earnings before interest, taxes, depreciation, and amortization (“EBITDA”) minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.

Effective Interest Rate

The Company’s average effective interest rate on its total debt during the nine months ended September 30, 2021 and 2020, was 2.15% and ~~2019, was~~ 3.79% ~~and 1.31%~~, respectively. Interest expense in the consolidated statements of ~~income~~operations included amortization of deferred

debt issuance costs for the three and nine months ended September 30, 2021 and 2020, ~~and 2019,~~ of ~~$0.3~~$0.2 million and ~~0.1~~$0.3 million, respectively, and ~~$1.0~~$0.9 million and ~~$0.1~~$1.0 million, respectively.

~~Table of Contents~~

Lines of Credit – Related Party

~~NMM Business Loan~~

On June 14, 2018, NMM amended its promissory note agreement with Preferred Bank (“NMM Business Loan Agreement”), which provides for loan availability of up to $20.0 million with a maturity date of June 22, 2020. One of the Company’s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September 1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October 31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal “prime rate,” plus 0.125%, or 5.625% as of December 31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amount outstanding as of June 30, 2019, of $5.0 million was fully repaid on September 11, 2019.

On September 5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September 5, 2019. This credit facility was subsequently amended on April 17, 2019, and July 29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal “prime rate,” plus 0.125%, or 3.375% as of September 30, 2020, and 4.875% as of December 31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.

On September 11, 2019, the NMM Business Loan Agreement, dated as of June 14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September 5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility. Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of September 30, 2020, outstanding letters of credit totaled $8.2 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.

APC Business Loan

On ~~June 14, 2018,~~September 10, 2019, the APC ~~amended its promissory note agreement~~Business Loan Agreement with Preferred Bank ~~which provides for loan availability of up to $10.0 million with a maturity date of June 22, 2020. This credit facility~~(the “APC Business Loan Agreement”) was subsequently amended on April 17, 2019, and June 11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December 31, 2020. On August 1, 2019, and September 10, 2019, this credit facility was further amended to ~~increase loan availability from $40.0 million to $43.8 million, and~~ decrease loan availability ~~from $43.8 million~~ to $4.1 ~~million, respectively.~~million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC’s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. ~~The interest rate~~One of the Company’s board members is ~~based on~~ the ~~Wall Street Journal “prime rate,” plus 0.125%, or 3.375%~~chairman and ~~4.875% as~~CEO of ~~September 30, 2020 and December 31, 2019, respectively.~~

~~As of September 30, 2020 and December 31, 2019, there was 0 availability under this line of credit.~~Preferred Bank.

Standby Letters of Credit

~~On October 2, 2018,~~ APAACO established ~~a second~~an irrevocable standby letter of credit with Preferred Bank, ~~(through~~which is affiliated with one of the ~~NMM Business Loan Agreement) for $6.6~~Company’s board members, totaling $14.8 million for the benefit of CMS. ~~The letter of credit expires on December 31,~~In August 2020, ~~and is automatically extended without amendment for additional one-year periods from~~ the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank’s notification of non-renewal. Thisirrevocable standby letter of credit was subsequently amended on August 14, 2019, to increase the amount from $6.6 million to $14.8 million and extended the expiration date to December 31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility, this letter of credit was terminated and reissued under the Credit Agreement.released by CMS. As of September 30, ~~2020, APAACO terminated $6.6~~2021, there were 0 outstanding letters of credit and the Company had $25.0 million ofavailable under the ~~irrevocable standby letter of credit.~~

~~Table of Contents~~

Amended Credit Facility.

APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.

Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.

10. Mezzanine and Stockholders’ Equity

Mezzanine

As the redemption feature of the APC shares (see Note 2) ~~of the shares~~ is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC’s shares ~~are~~were not redeemable, and it iswas not probable that the shares ~~will~~would become redeemable, as of September 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

Stockholders’ Equity

As of September 30, ~~2020, 302,732~~2021, 141,638 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the ~~merger between NMM and ApolloMed in December~~ 2017 ~~(the "Merger"),~~Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.

~~See options~~
Treasury Stock

APC owned 10,925,702 and ~~warrants section below for~~12,323,164 shares of ApolloMed’s common stock as of September 30, 2021 and December 31, 2020, respectively, which are legally issued ~~upon exercise~~and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. In March 2021, the Company issued 34,158 shares of common stock to APC as a result of APC exercising their warrants.

Dividends

During the three months ended September 30, 2021 and 2020, APC paid dividends of $10.0 million and $19.9 million, respectively. During the nine months ended September 30, 2021 and 2020, APC paid dividends of $29.9 million and $49.5 million, respectively.

During the three months ended September 30, 2021 and 2020, CDSC did not pay any dividends. During the nine months ended September 30, 2021 and 2020, CDSC paid dividends of $1.5 million and $0.6 million, respectively.

11. Stock-Based Compensation

The following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans for the three and nine months ended September 30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and ~~stock purchase warrants.~~administrative expenses in the accompanying consolidated statements of operations (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Stock options	$	602	$	298	$	1,794	$	1,270
Restricted stock awards	818		350		2,528		1,288

Total share-based compensation expense	$	1,420	$	648	$	4,322	$	2,558

Unrecognized compensation expense related to total share-based payments outstanding as of September 30, 2021, was $7.4 million.

Options

The Company’s outstanding stock options consisted of the following:


		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)			Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Options outstanding at January 1, 2020		607,346	$	9.22	3.42	$	5,600
Options outstanding at January 1, 2021								Options outstanding at January 1, 2021	725,864	$	13.25	3.75	$	3,400
Options granted	Options granted	11,742	18.41		—	—		Options granted	24,437	23.24		—	—
Options exercised	Options exercised	(120,000)	2.58		—	1,800		Options exercised	(40,000)	5.20		—	2,800
Options forfeited	Options forfeited	(12,228)	17.57		—	—		Options forfeited	(9,826)	3.89		—	—

Options outstanding at September 30, 2020		486,860	$	10.86	3.45	$	3,300
Options outstanding at September 30, 2021								Options outstanding at September 30, 2021	700,475	$	14.18	3.18	$	53,800

Options exercisable at September 30, 2020		405,833	$	7.91	2.75	$	3,500
Options exercisable at September 30, 2021								Options exercisable at September 30, 2021	534,638	$	9.71	2.24	$	41,900

During the nine months ended September 30, ~~2020 and 2019, stock~~2021, options were exercised for ~~120,000 and 203,524~~40,000 shares ~~respectively,~~ of the Company’s common stock, ~~which resulted~~resulting in proceeds of ~~approximately $0.3 million and $1.2 million, respectively. The exercise price ranged from $2.10 to $5.00 per share for the exercises during~~$0.2 million. During the nine months ended September 30, 2020, ~~and ranged from $1.50 to $10.00 per share~~options were exercised for 120,000 shares of the ~~exercises during the nine months ended September 30, 2019.~~

~~Table~~Company’s common stock, resulting in proceeds of ~~Contents~~

approximately $0.3 million.

During the nine months ended September 30, ~~2020 and 2019, 0 stock options were exercised pursuant to the cashless exercise provision.~~

~~During the nine months ended September 30, 2020,~~2021, the Company granted ~~11,742~~24,437 stock options with a vesting period of ~~five-years~~two years to certain ApolloMed ~~board members~~executives with an exercise price of ~~$18.41,~~$23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:


September 30, ~~2020~~2021	~~Board Members~~Executives
Expected term	~~3.0~~3.5 years
Expected volatility	~~90.01~~81.10		%
Risk-free interest rate	~~1.43~~0.19		%
Market value of common stock	$	~~10.56~~12.86
Annual dividend yield	0—		%
Forfeiture rate	0—		%

Restricted Stock Awards

The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day’s closing market price of the Company’s common stock. During the nine months ended September 30, ~~2020,~~2021, the Company granted restricted stock awards totaling ~~97,447~~159,267 shares with a weighted average grant date fair value of ~~$17.58.~~$28.24. The grant date fair value of the restricted stock was ~~$1.6~~$4.5 million and will be recognized on a straight-line basis over the awards’ vesting period of one to three years.

During the three and nine months ended September 30, 2020, the Company recorded approximately $0.6 million and $2.2 million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which are included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of September 30, 2020, was $3.1 million.

Warrants

The Company’s outstanding warrants consisted of the following:


		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)			Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Warrants outstanding at January 1, 2020		3,154,590	$	9.96	2.01	$	26,700
Warrants outstanding at January 1, 2021								Warrants outstanding at January 1, 2021	1,878,126	10.39		1.63	14,800
Warrants granted	Warrants granted	0	0		—	0		Warrants granted	—	—		—	—
Warrants exercised	Warrants exercised	(800,709)	9.22		—	6,000		Warrants exercised	(624,760)	10.23		—	20,618
Warrants expired/forfeited	Warrants expired/forfeited	0	0		—	0		Warrants expired/forfeited	(17,803)	9.72		—	—

Warrants outstanding at September 30, 2020		2,353,881	$	10.21	1.62	$	18,200
Warrants outstanding at September 30, 2021								Warrants outstanding at September 30, 2021	1,235,563	$	10.49	1.19	99,500

Exercise Price Per Share Warrants
Outstanding
Weighted
Average
Remaining
Contractual Life
Warrants
Exercisable
Weighted
Average
Exercise Price
Per Share
$ 9.00 305,812 0.04 305,812 $ 9.00
10.00 1,248,779 1.64 1,248,779 10.00
11.00 799,290 2.19 799,290 11.00
$ $ 9.00 –11.00 2,353,881 1.62 2,353,881 $ 10.21

~~Table of Contents~~


Exercise Price Per Share		Warrants Outstanding	Weighted Average Remaining Contractual Life	Warrants Exercisable	Weighted Average Exercise Price Per Share
$	10.00	635,428	1.19	635,428	$	10.00
11.00		600,135	1.19	600,135	$	11.00

$ 10.00 – 11.00		1,235,563	1.19	1,235,563	$	10.49

During the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, common stock warrants were exercised for 624,760 and 800,709 ~~and 133,221~~ shares ~~respectively,~~ of the Company’s common stock, respectively, which resulted in proceeds of approximately ~~$6.2~~$6.4 million and ~~$1.2~~$6.2 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the nine months ended September 30, ~~2020~~2021 and ~~2019, respectively.~~

~~During the nine months ended September 30,~~ 2020, ~~common stock warrants were exercised on a cashless basis for 127,022 shares of the Company's common stock which resulted in the Company issuing 66,517 net shares.~~

~~Treasury Stock~~

APC owned 17,307,214 and 17,290,317 shares of ApolloMed’s common stock as of September 30, 2020 and December 31, 2019, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).

During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of September 30, 2020, the brokerage account only held shares of ApolloMed totaling $7.6 million, and as such the ApolloMed shares in the brokerage account have been recorded as treasury shares.

~~Dividends~~

~~During the nine months ended September 30, 2020 and 2019, APC paid dividends of $49.5 million and $59.7 million, respectively.~~

~~During the nine months ended September 30, 2020 and 2019, CDSC paid dividends of $0.6 million and $1.2 million,~~ respectively.

~~11.~~

12. Commitments and Contingencies

Regulatory Matters

Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.

As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California ~~DMHC~~Department of Managed Healthcare (“DMHC”) regulations, including maintenance of minimum working capital, tangible net equity (“TNE”), cash-to-claims ratio, and claims payment requirements prescribed by the ~~California~~ DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. ~~At September 30, 2020 and December 31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.~~

Many of the ~~Company’s~~ payor and provider contracts with the Company’s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.

Standby Letters of Credit

As part of the APAACO participation with CMS, the Company must provide a financial guarantee to ~~CMS, the~~CMS. The guarantee generally must be in an amount equal to 2% of the Company’s benchmark Medicare Part A and Part B expenditures. ~~The Company has established an irrevocable standby letter~~In August 2020, $14.8 million of ~~credit under~~ the ~~Credit Agreement for a face amount of $8.2 million for the 2019 performance year (see Note 9).~~

~~APC established~~ irrevocable standby letters of credit ~~with a financial institution for a total~~were released by CMS and no amounts remained outstanding as of ~~$0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods~~September 30, 2021.

~~Table of Contents~~

~~from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).~~

APC and Alpha Care established irrevocable standby letters of credit with a ~~financial institution~~Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminatedplans (see Note 9).

Litigation

From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company’s financial condition, cash flows, or results of operations.

~~Prospect Medical Systems~~

On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, “Prospect”) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG’s purported business plans, seeking damages in excess of $5.0 million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect’s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues.

Liability Insurance

The Company believes that its insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company’s affiliated professional organizations or the Company’s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business. Contracted physicians are required to obtain their own insurance coverage.

Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to the Company in future years at acceptable costs, and on favorable terms.

~~12.~~13. Related-Party Transactions

On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a 48.9% owned equity method investee (see Note 5), in the amount of $5.0 million. On June 28, 2018 and November 28, 2018, UCAP entered into 2 additional subordinated note receivable agreements with UCI in the amount of $2.5 million and $5.0 million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright (see Note 6).

During the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, NMM earned approximately ~~$4.2~~$4.5 million and ~~$4.4~~$4.2 million, respectively, and ~~$12.6~~$13.2 million and ~~$12.9~~$12.6 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA’s IPA line of business (see Note 5).

During the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC paid approximately ~~$0.5~~$0.7 million and ~~$0.7~~$0.5 million, respectively, and ~~$1.5~~$1.7 million and ~~$2.1~~$1.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on ~~40% equity ownership interest held by APC (see Note 5).~~

~~Table of Contents~~

~~During~~ the three and nine months ended September 30, 2020 and 2019, APC paid approximately $1.2 million and $2.0 million, respectively, and $3.8 and $5.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).

During the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC paid approximately $2.2 million and $1.2 million, respectively, and $5.4 million and $3.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5).

During the three and nine months ended September 30, 2021 and 2020, APC paid approximately $0.3 million and $0.1 million, respectively, and $0.4 million and $0.2 million ~~respectively,~~ to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.

During the three and nine months ended September 30, 2021 and 2020, APC paid approximately $24,000 and ~~2019,~~$23,000, respectively, and $0.1 million and $0.1 million, respectively, to Fresenius Medical Care (“Fresenius”) and its subsidiaries for services as a provider. During the three and nine months ended September 30, 2021 and 2020, APAACO paid approximately $0.2 million and $0.2 million, respectively, and $0.5 million and $0.5 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company’s board members is an officer of Fresenius.

During the three and nine months ended September 30, 2021 and 2020, APC paid approximately $0.7 million and $0.1 million, respectively, and $1.1 million and $0.1 million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company’s board members is a board member of Fulgent Genetics, Inc.

During the three months ended September 30, 2021 and 2020, APC paid an aggregate of approximately $10.1 million and $7.1 million ~~and $6.7 million,~~to shareholders, respectively, which ~~include~~included approximately ~~$1.7~~$1.8 million and ~~$1.8~~$1.7 million, respectively, to shareholders who are also officers of APC. During the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, APC paid an aggregate of approximately of$25.3 million and $23.4 million ~~and $23.1 million, respectively,~~ to shareholders, ~~of APC for provider services, which include approximately $6.5~~respectively, and $5.6 million and ~~$6.9~~$6.5 million, respectively, to shareholders who are also officers of APC.

During the three and nine months ended September 30, ~~2020~~2021 and 2019, NMM paid approximately $0.3 million, respectively and $0.8 million, respectively, to Medical Property Partners (“MPP”) for an office lease. MPP shares common ownership with certain board members of NMM.

~~During the three and nine months ended September 30,~~ 2020, NMM paid approximately $0.4 million and $1.1 million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly 50% owned by Drs. Sim and Lam. As of September 30, 2020, the Company had $10.4 million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.

~~During the three months ended September 30, 2020 and 2019,~~ the Company paid approximately $0 and $39,000, respectively, and ~~$0.1~~$0 and $0.3 million, respectively, ~~and paid approximately $0.3 million for both the nine months ended September 30, 2020 and 2019,~~ to Critical Quality Management Corporation (“CQMC”) for an office lease. CQMC shares common ownership with certain board members of APC.

For ~~both~~ the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.3 million and $0.3 million, respectively, to Numen, LLC (“Numen”) for an office lease. Numen is owned by a shareholder of APC. ~~As of~~

During the three and nine ended September 30, 2021 and 2020, ~~the Company had $1.4~~APC paid approximately $0.4 million ~~of ROU assets~~ and ~~lease liabilities,~~$0.4 million, respectively, ~~related~~and $1.1 million and $1.1 million, respectively, to ~~its~~One MSO for an office lease, ~~with Numen to be amortized over~~which is accounted for under the ~~remaining life of the lease.~~equity method based on 50% equity ownership interest held by APC (see Note 5).

The Company has agreements with ~~HSMSO,~~Health Source MSO Inc., a California corporation (“HSMSO”), Aurion Corporation (“Aurion”), and AHMC Healthcare Inc. (“AHMC”) for services provided to the Company. One of the Company’s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company’s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2020		2019		2020		2019			2021		2020		2021		2020
AHMC – Risk pool, capitation, claims payment, net		$	5,683	$	11,215	$	23,739	$	39,165
AHMC – Risk pool, capitation, claims payment										AHMC – Risk pool, capitation, claims payment	$	10,712	$	5,683	$	36,505	$	23,739
HSMSO – Management fees, net	HSMSO – Management fees, net	(109)		(160)		(430)		(1,075)		HSMSO – Management fees, net	(33)		(109)		(141)		(430)
Aurion – Management fees	Aurion – Management fees	(100)		(76)		(228)		(232)		Aurion – Management fees	(100)		(100)		(252)		(228)

Net total		$	5,474	$	10,979	$	23,081	$	37,858
Receipts, net										Receipts, net	$	10,579	$	5,474	$	36,112	$	23,081

The Company and AHMC have a ~~risk sharing~~risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, the Company has recognized risk pool revenue under this agreement of $21.5 million and $10.5 million, and ~~$11.0~~$47.1 million ~~respectively,~~ and $31.5 million, ~~and $31.9 million, respectively, for~~respectfully, of which ~~$36.9~~$47.9 million and ~~$40.4~~$45.3 million remained outstanding as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

During the ~~three and~~ nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, NMM paid approximately ~~$0 and $0.1 million, respectively,~~$44,000 and $27,000, ~~and $0.2 million,~~ respectively, to an ApolloMed board member ~~Matthew Mazdyasni,~~for consulting services. During the three months ended September 30, 2021 and 2020, there were no payments to such ApolloMed board member for consulting services.

In addition, affiliates wholly owned by the Company’s officers, including the ~~Company's~~Company’s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of ~~income~~operations on a consolidated basis, together with the Company’s

~~Table of Contents~~

subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related-party transactions.

For equity method investments, loans receivable, and line of credits from related parties, see Notes 5, 6, and 9, respectively.

~~13.~~14. Income Taxes

The Company uses the liability method of accounting for income taxes as set forth in ASC ~~740.~~740 Income Taxes. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.

On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision ~~(benefit)~~ in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company’s estimated effective tax rate. When this occurs, the income tax provision ~~(benefit)~~ is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company’s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.

As of September 30, ~~2020,~~2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.

The Company’s effective income tax rate for the nine months ended September 30, ~~2020~~2021 and September 30, ~~2019 were~~2020, was 31.5% and 28.8% ~~and 25.5%~~, ~~respectively, and~~respectively. The tax rate for the nine months ended September 30, 2021, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.

As of September 30, ~~2020,~~2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.

The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries’ state and ~~Federal~~federal income tax returns are open to audit under the statute of limitations for the years ended December 31, ~~2015~~2016 through December 31, ~~2018,~~2020, and for the years ended December 31, ~~2016~~2017 through December 31, ~~2018,~~2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. However, the benefits of the CARES Act are not expected to impact the Company’s annual estimated tax rate for the nine months ended September 30, 2020.

~~14.~~15. Earnings Per Share

Basic earnings per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.

As of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, APC held ~~17,307,214~~10,925,702 and ~~17,290,317~~12,323,164 shares of ApolloMed’s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.

~~Table of Contents~~

Below is a summary of the earnings per share computations:


Three Months Ended September 30,	Three Months Ended September 30,	2020		2019		Three Months Ended September 30,	2021		2020
Earnings per share – basic	Earnings per share – basic	$	0.46	$	0.11	Earnings per share – basic	$	0.77	$	0.46
Earnings per share – diluted	Earnings per share – diluted	$	0.45	$	0.10	Earnings per share – diluted	$	0.74	$	0.45
Weighted average shares of common stock outstanding – basic	Weighted average shares of common stock outstanding – basic	36,364,839		34,643,754		Weighted average shares of common stock outstanding – basic	44,301,060		36,364,839
Weighted average shares of common stock outstanding – diluted	Weighted average shares of common stock outstanding – diluted	37,551,740		37,792,266		Weighted average shares of common stock outstanding – diluted	46,273,640		37,551,740


Nine Months Ended September 30,	Nine Months Ended September 30,	2020		2019		Nine Months Ended September 30,	2021		2020
Earnings per share – basic	Earnings per share – basic	$	0.77	$	0.21	Earnings per share – basic	$	1.38	$	0.77
Earnings per share – diluted	Earnings per share – diluted	$	0.75	$	0.20	Earnings per share – diluted	$	1.33	$	0.75
Weighted average shares of common stock outstanding – basic	Weighted average shares of common stock outstanding – basic	36,149,692		34,555,124		Weighted average shares of common stock outstanding – basic	43,608,116		36,149,692
Weighted average shares of common stock outstanding – diluted	Weighted average shares of common stock outstanding – diluted	37,249,967		37,816,698		Weighted average shares of common stock outstanding – diluted	45,339,372		37,249,967

Below is a summary of the shares included in the diluted earnings per share computations:


Three Months Ended September 30,	Three Months Ended September 30,	2020	2019	Three Months Ended September 30,	2021	2020
Weighted average shares of common stock outstanding – basic	Weighted average shares of common stock outstanding – basic	36,364,839	34,643,754	Weighted average shares of common stock outstanding – basic	44,301,060	36,364,839
10% shares held back pursuant to indemnification clause		0	1,511,332

Stock options	Stock options	187,843	299,536	Stock options	583,639	187,843
Warrants	Warrants	960,806	1,337,644	Warrants	1,083,216	960,806
Restricted stock awards	Restricted stock awards	38,252	0	Restricted stock awards	305,725	38,252
Weighted average shares of common stock outstanding – diluted	Weighted average shares of common stock outstanding – diluted	37,551,740	37,792,266	Weighted average shares of common stock outstanding – diluted	46,273,640	37,551,740


Nine Months Ended September 30,	Nine Months Ended September 30,	2020	2019	Nine Months Ended September 30,	2021	2020
Weighted average shares of common stock outstanding – basic	Weighted average shares of common stock outstanding – basic	36,149,692	34,555,124	Weighted average shares of common stock outstanding – basic	43,608,116	36,149,692
10% shares held back pursuant to indemnification clause		0	1,511,332

Stock options	Stock options	178,445	307,665	Stock options	498,296	178,445
Warrants	Warrants	890,489	1,442,577	Warrants	971,935	890,489
Restricted stock awards	Restricted stock awards	31,341	0	Restricted stock awards	261,025	31,341
Weighted average shares of common stock outstanding – diluted	Weighted average shares of common stock outstanding – diluted	37,249,967	37,816,698	Weighted average shares of common stock outstanding – diluted	45,339,372	37,249,967

~~Table of Contents~~

~~15.~~16. Variable Interest Entities (VIEs)

A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.

The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 – “Basis of Presentation and Summary of Significant Accounting ~~Policies”~~Policies - Variable Interest Entities” to the accompanying consolidated financial statements for information on how the Company determines VIEs and ~~its~~their treatment.

The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the ~~Company, nor do creditors~~general credit of ApolloMed, as the primary beneficiary of the ~~Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care.~~VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).

September 30,
2020 December 31,
2019
Assets
Current assets
Cash and cash equivalents $ 94,751 $ 87,110
Restricted cash 0 75
Investment in marketable securities 118,262 123,948
Receivables, net 15,365 9,300
Receivables, net – related party 39,506 42,976
Other receivables 734 744
Prepaid expenses and other current assets 9,667 7,403
Loan receivable 6,425 6,425
Loan receivable – related parties 0 16,500
Total current assets 284,710 294,481
Noncurrent assets
Land, property and equipment, net 8,877 9,547
Intangible assets, net 72,107 81,439
Goodwill 109,460 108,913
Investment in affiliates 310,491 318,315
Investment in privately held entities 36,584 1,615
Investments in other entities – equity method 27,268 28,427
Restricted cash 746 746
Operating lease right-of-use assets 6,654 4,751
Other assets 20,736 1,057
Total noncurrent assets 592,923 554,810
Total assets $ 877,633 $ 849,291
Current liabilities
Accounts payable and accrued expenses $ 13,444 $ 11,187

~~Table of Contents~~

September 30,
2020 December 31,
2019
Fiduciary accounts payable 3,986 2,027
Medical liabilities 42,546 49,019
Income taxes payable 15,408 4,530
Amount due to affiliate 22,131 28,058
Dividends payable 485 271
Finance lease liabilities 102 102
Operating lease liabilities 1,300 1,088
Total current liabilities 99,402 96,282
Noncurrent liabilities
Deferred tax liability 7,725 14,059
Finance lease liabilities, net of current portion 337 416
Operating lease liabilities, net of current portion 5,512 3,742
Total noncurrent liabilities 13,574 18,217
Total liabilities $ 112,976 $ 114,499

The assets and liabilities of the Company’s other consolidated VIEs were not considered significant.


	September 30, 2021		December 31, 2020
Assets

Current assets
Cash and cash equivalents	$	121,258	$	126,158
Investment in marketable securities	124,569		67,637
Receivables, net	15,927		5,155
Receivables, net – related party	50,454		46,718
Income taxes receivable	4,267		—
Other receivables	293		1,084
Prepaid expenses and other current assets	9,808		14,863
Loan receivable – related party	4,000		—
Amount due from affiliate	15,764		—
Total current assets	346,340		261,615

Noncurrent assets
Land, property and equipment, net	47,253		27,599
Intangible assets, net	61,140		69,250
Goodwill	109,460		109,460
Loans receivable – related parties	104		4,145
Investment in affiliates	994,785		225,144
Investments in other entities – equity method	45,046		43,516
Investment in privately held entities	405		36,584
Restricted cash	—		500
Operating lease right-of-use assets	5,258		6,298
Other assets	2,533		17,177

Total noncurrent assets	1,265,984		539,673

Total assets	$	1,612,324	$	801,288

Current liabilities


	September 30, 2021		December 31, 2020
Accounts payable and accrued expenses	$	15,202	$	12,963
Fiduciary accounts payable	8,827		9,642
Medical liabilities	34,998		37,684
Income taxes payable	—		4,225
Dividends payable	556		485
Amount due to affiliate	—		22,698
Current portion of long-term debt	207		201
Finance lease liabilities	110		102
Operating lease liabilities	1,231		1,242

Total current liabilities	61,131		89,242

Noncurrent liabilities
Long-term debt, net of current portion and deferred financing costs	7,245		7,379
Deferred tax liability	18,941		9,144
Finance lease liabilities, net of current portion	221		311
Operating lease liabilities, net of current portion	4,262		5,242
Other long-term liabilities	1,010		—

Total noncurrent liabilities	31,679		22,076

Total liabilities	$	92,810	$	111,318

~~Table of Contents~~

~~16.~~17. Leases

The Company has operating and finance leases for corporate offices, ~~doctors’~~physicians’ offices, and certain equipment. These leases have remaining lease terms of 1one month to 5five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, assets recorded under finance leases were ~~$0.4~~$0.3 million and ~~$0.5~~$0.4 million, respectively, and accumulated depreciation associated with finance leases were ~~$0.3~~$0.5 million ~~for both periods.~~and $0.4 million, respectively.

Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.

Leases with an initial term of 12 months or less are not recorded on the balance sheet.

The components of lease expense were as follows (in thousands):


		Three Months Ended September 30,					Three Months Ended September 30,
		2020		2019			2021		2020

Operating lease cost	Operating lease cost	$	1,784	$	1,489	Operating lease cost	$	1,379	$	1,784

Finance lease cost	Finance lease cost					Finance lease cost
Amortization of lease expense	Amortization of lease expense	26		26		Amortization of lease expense	27		26
Interest on lease liabilities	Interest on lease liabilities	3		4		Interest on lease liabilities	3		3

Sublease income	Sublease income	(206)		(103)		Sublease income	(235)		(206)

Total finance lease cost, net		$	1,607	$	1,416
Total lease cost, net						Total lease cost, net	$	1,174	$	1,607


		Nine Months Ended September 30,					Nine Months Ended September 30,
		2020		2019			2021		2020

Operating lease cost	Operating lease cost	$	5,172	$	3,832	Operating lease cost	$	3,893	$	5,172

Finance lease cost	Finance lease cost					Finance lease cost
Amortization of lease expense	Amortization of lease expense	78		76		Amortization of lease expense	81		78
Interest on lease liabilities	Interest on lease liabilities	11		13		Interest on lease liabilities	8		11

Sublease income	Sublease income	(567)		(309)		Sublease income	(709)		(567)

Total finance lease cost, net		$	4,694	$	3,612
Total lease cost, net						Total lease cost, net	$	3,273	$	4,694

~~Table of Contents~~

Other information related to leases was as follows (in thousands):


		Three Months Ended September 30,							Three Months Ended September 30,
		2020			2019				2021			2020

Supplemental Cash Flows Information
Supplemental Cash Flow Information								Supplemental Cash Flow Information

Cash paid for amounts included in the measurement of lease liabilities:	Cash paid for amounts included in the measurement of lease liabilities:							Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	Operating cash flows from operating leases	$	1,489		$	1,677		Operating cash flows from operating leases	$	1,414		$	1,489
Operating cash flows from finance leases	Operating cash flows from finance leases	$	3		$	4		Operating cash flows from finance leases	3			3
Financing cash flows from finance leases	Financing cash flows from finance leases	$	26		$	26		Financing cash flows from finance leases	27			26

Right-of-use assets obtained in exchange for lease liabilities:	Right-of-use assets obtained in exchange for lease liabilities:							Right-of-use assets obtained in exchange for lease liabilities:
Operating leases	Operating leases	$	0		$	0		Operating leases	$	—		—

		Nine Months Ended September 30,							Nine Months Ended September 30,
		2020			2019				2021			2020

Supplemental Cash Flows Information
Supplemental Cash Flow Information								Supplemental Cash Flow Information

Cash paid for amounts included in the measurement of lease liabilities:	Cash paid for amounts included in the measurement of lease liabilities:							Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	Operating cash flows from operating leases	$	4,369		$	3,950		Operating cash flows from operating leases	$	3,903		$	4,369
Operating cash flows from finance leases	Operating cash flows from finance leases	$	11		$	13		Operating cash flows from finance leases	8			11
Financing cash flows from finance leases	Financing cash flows from finance leases	$	78		$	76		Financing cash flows from finance leases	81			78

Right-of-use assets obtained in exchange for lease liabilities:	Right-of-use assets obtained in exchange for lease liabilities:							Right-of-use assets obtained in exchange for lease liabilities:
Operating leases	Operating leases	$	7,652		$	15,417		Operating leases	$	—		$	7,652

		Nine Months Ended September 30,							Nine Months Ended September 30,
		2020			2019				2021			2020

Weighted Average Remaining Lease Term	Weighted Average Remaining Lease Term							Weighted Average Remaining Lease Term

Operating leases	Operating leases	6.93 years			6.80 years			Operating leases	6.44 years			6.93 years
Finance leases	Finance leases	3.92 years			4.92 years			Finance leases	2.92 years			3.92 years

Weighted Average Discount Rate	Weighted Average Discount Rate							Weighted Average Discount Rate

Operating leases	Operating leases	6.10		%	6.12		%	Operating leases	6.10		%	6.10		%
Finance leases	Finance leases	3.00		%	3.00		%	Finance leases	3.00		%	3.00		%

~~Table of Contents~~

Future minimum lease payments under non-cancellable leases as of September 30, ~~2020~~2021, is as follows (in thousands):


September 30, 2020		Operating Leases		Finance Leases
2020 (excluding the nine months ended September 30, 2020)		$	1,173	$	30
2021		4,297		119
September 30, 2021						September 30, 2021	Operating Leases		Finance Leases
2021 (excluding the nine months ended September 30, 2021)						2021 (excluding the nine months ended September 30, 2021)	$	950	$	29
2022	2022	3,529		119		2022	3,529		119
2023	2023	3,303		119		2023	3,303		119
2024	2024	2,940		79		2024	2,940		79
2025						2025	2,648		—
Thereafter	Thereafter	9,459		0		Thereafter	6,811		—

Total future minimum lease payments	Total future minimum lease payments	24,701		466		Total future minimum lease payments	20,181		346
Less: imputed interest	Less: imputed interest	4,795		27		Less: imputed interest	3,667		15
Total lease liabilities	Total lease liabilities	19,906		439		Total lease liabilities	16,514		331
Less: current portion	Less: current portion	3,290		102		Less: current portion	2,658		110
Long-term lease liabilities	Long-term lease liabilities	$	16,616	$	337	Long-term lease liabilities	$	13,856	$	221

As of September 30, ~~2020,~~2021, the Company does not have additional operating and finance leases that have not yet commenced.

~~17.~~18. Subsequent Events

~~Dividend~~

In September 2020, APC's board of directors declared an in-kind dividend of 5 million shares of ApolloMed's common stock on a pro rata basis to APC's shareholders in November 2020. The shares being distributed is from the Excluded Assets that remain solely for the benefit of APC and its shareholders.

~~Promissory note~~DMG

In October ~~2020, APC~~2021, the Company entered into ~~a promissory note with AHMC, a related party~~an agreement to purchase within three years all of the remaining equity interests in DMG. The Company ~~(the “2020 Note”) as payee for~~currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years. In accordance with relevant accounting guidance, the Company has determined that DMG is a ~~principal sum of $4.0 million with a maturity date of two years from the date~~variable interest entity of the ~~agreement. The contractual interest rate on~~Company; therefore, DMG's financial statements will be consolidated with those of the 2020 Note is 3.75% per annum. The funds lent pursuant to the 2020 Note are the same funds that were deposited for investment opportunities in March 2020 (the "March Deposit"). As with the March Deposit, the 2020 Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH.Company.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following ~~management’s discussion~~Management’s Discussion and ~~analysis~~Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020, filed with the SEC on March ~~16, 2020.~~15, 2021.

Overview

We, together with our affiliated ~~physician~~physician-owned medical groups and consolidated entities, are a leading physician-centric, technology-enabled healthcare management company. Leveraging our proprietary population health management and healthcare delivery platform, we operate an integrated, value-based healthcare ~~model, which aims~~model. We aim to empower the healthcare providers in our network to deliver the highest quality of care to our patients in a cost-effective manner.

~~Table of Contents~~

Headquartered in Alhambra, California, our subsidiaries and VIEs include management services organizations ~~("MSOs"~~(“MSOs”), affiliated independent practice associations ~~("IPAs"~~(“IPAs”), and a Next Generation Accountable Care Organization ~~("NGACO"~~(“NGACO”). Network Medical Management, Inc. ~~("NMM"~~(“NMM”) and Apollo Medical Management, Inc. ~~("AMM"~~(“AMM”) are the administrative and managerial services companies for the affiliated ~~physician owned~~physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under ~~the~~brands including (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ~~("APC"~~(“APC”), (ii) Alpha Care Medical Group, Inc., and (iii) Accountable Health Care ~~IPA brands.~~IPA. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ~~("AMH"~~(“AMH”), and Southern California Heart Centers, a Medical Corporation ~~("SCHC"~~(“SCHC”). Our NGACO operates under the APA ACO, Inc. ~~("APAACO"~~(“APAACO”) brand and participates in the Centers for Medicare & Medicaid Services program, ~~that~~which allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward under an attribution-based risk-sharing model.

We, together with our affiliated physician-owned medical groups and consolidated entities, provide coordinated outcomes-based medical care primarily serving patients in California. The majority of our patients are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (“HMOs”). However, a small portion of our revenue comes from ~~participation~~non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (“ApolloMed”) and the following subsidiaries: NMM, AMM, and APAACO and their consolidated entities, including consolidated VIEs.

Led by a management team with several decades of experience, we are focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well positioned to take advantage of the shift in the ~~program's attribution-based risk sharing model.~~U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.

Through our NGACO model and a network of IPAs with more than 2,000 primary care physicians, 7,000 ~~contracted~~specialist physicians, 10 dual physicians, and 350 physician and specialist extenders, we are currently responsible for coordinating care for approximately 1.1 million patients in California.

Recent and Other Developments

OnDMG

In October 2021, the Company entered into an agreement to purchase within three years all of the remaining equity interests in DMG. The Company currently owns 40% of DMG and has committed to purchasing the remaining 60% within three years. In accordance with relevant accounting guidance, the Company has determined that DMG is a variable interest entity of the Company; therefore, DMG's financial statements will be consolidated with those of the Company.

Appointment and Departure of Certain Officers

In November ~~5, 2020,~~2021, the ~~Integrated Healthcare Association ("IHA") recognized Allied Pacific~~Company appointed Brandon Sim as its Co-Chief Executive Officer. With this appointment, Kenneth Sim, M.D. will no longer serve as Co-CEO of ~~California IPA for our exceptional performance. Allied Pacific~~ApolloMed but will continue in his role as Executive Chairman. Over the past several months, Mr. Sim has taken leadership of ~~California IPA performed in~~ the ~~top 10 percent~~Company’s corporate strategy, operations and engineering teams, and he will continue to lead all these aspects of all participating physicians organizations in the Total Cost of Care Domain during measurement year 2019 in IHA's Align. Measure. Perform. ("AMP") Commercial HMO program. IHA honors physicians organizations with the highest level of performance for each AMP Commercial HMO measurement domain.ApolloMed��s business as Co-CEO.

Key Financial Measures and Indicators

Operating Revenues

Our revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO AIPBP revenue, management fee income, and FFS revenue. The form of billing and related risk of collection for such services may vary by type of revenue and the customer.

Operating Expenses

Our largest ~~expense is~~expenses are the patient care cost paid to contracted physicians and the cost of providing management and administrative support services to our affiliated physician groups. These management services include ~~providing~~ utilization and case management, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.

5253

~~Table of Contents~~

Results of Operations

Apollo Medical Holdings, Inc.

Consolidated Statements of ~~Income~~Operations

(In thousands)

(Unaudited)


		Three Months Ended September 30,									Three Months Ended September 30,
		2020		2019		$ Change		% Change			2021		2020		$ Change		% Change
Revenue	Revenue									Revenue
Capitation, net	Capitation, net	$	135,032	$	130,807	$	4,225	3	%	Capitation, net	$	149,059	$	135,032	$	14,027	10	%
Risk pool settlements and incentives	Risk pool settlements and incentives	30,916		11,355		19,561		172	%	Risk pool settlements and incentives	59,923		30,916		29,007		94	%
Management fee income	Management fee income	8,707		8,518		189		2	%	Management fee income	9,652		8,707		945		11	%
Fee-for-services, net	Fee-for-services, net	3,737		4,100		(363)		(9)	%	Fee-for-services, net	7,260		3,737		3,523		94	%
Other income	Other income	1,731		1,280		451		35	%	Other income	1,223		1,731		(508)		(29)	%
Total revenue	Total revenue	180,123		156,060		24,063		15	%	Total revenue	227,117		180,123		46,994		26	%

Operating expenses	Operating expenses									Operating expenses
Cost of services		121,823		131,130		(9,307)		(7)	%
Cost of services, excluding depreciation and amortization										Cost of services, excluding depreciation and amortization	147,473		121,823		25,650		21	%
General and administrative expenses	General and administrative expenses	16,270		7,950		8,320		105	%	General and administrative expenses	21,813		16,270		5,543		34	%
Depreciation and amortization	Depreciation and amortization	4,674		4,920		(246)		(5)	%	Depreciation and amortization	4,671		4,674		(3)		—	%
Impairment of intangibles		—		1,994		(1,994)		(100)	%

Total expenses	Total expenses	142,767		145,994		(3,227)		(2)	%	Total expenses	173,957		142,767		31,190		22	%

Income from operations	Income from operations	37,356		10,066		27,290		271	%	Income from operations	53,160		37,356		15,804		42	%

Other income
Other (expense) income										Other (expense) income
Income from equity method investments	Income from equity method investments	403		2,054		(1,651)		(80)	%	Income from equity method investments	132		403		(271)		(67)	%
Gain on sale of equity method investment										Gain on sale of equity method investment	2,193		—		2,193		100	%
Interest expense	Interest expense	(2,466)		(828)		(1,638)		198	%	Interest expense	(967)		(2,466)		1,499		(61)	%
Interest income	Interest income	752		509		243		48	%	Interest income	420		752		(332)		(44)	%
Unrealized loss on investments										Unrealized loss on investments	(60,943)		—		(60,943)		(100)	%
Other income	Other income	130		2,620		(2,490)		(95)	%	Other income	500		130		370		285	%
Total other (expense) income, net		(1,181)		4,355		(5,536)		(127)	%
Total other expense, net										Total other expense, net	(58,665)		(1,181)		(57,484)		*

Income before provision for income taxes		36,175		14,421		21,754		151	%
(Loss) income before (benefit from) provision for income taxes										(Loss) income before (benefit from) provision for income taxes	(5,505)		36,175		(41,680)		(115)	%

Provision for income taxes		10,751		3,682		7,069		192	%
(Benefit from) provision for income taxes										(Benefit from) provision for income taxes	(120)		10,751		(10,871)		(101)	%

Net income		25,424		10,739		14,685		137	%
Net (loss) income										Net (loss) income	(5,385)		25,424		(30,809)		(121)	%

Net income attributable to noncontrolling interest		8,711		7,035		1,676		24	%
Net (loss) income attributable to noncontrolling interest										Net (loss) income attributable to noncontrolling interest	(39,664)		8,711		(48,375)		*

Net income attributable to Apollo Medical Holdings, Inc.	Net income attributable to Apollo Medical Holdings, Inc.	$	16,713	$	3,704	$	13,009	351	%	Net income attributable to Apollo Medical Holdings, Inc.	$	34,279	$	16,713	$	17,566	105	%

* Percentage change of over 500%

5354

~~Table of Contents~~

For the Nine Months Ended September 30,
2020 2019 $ Change % Change
Revenue
Capitation, net $ 416,402 $ 305,548 $ 110,854 36 %
Risk pool settlements and incentives 54,155 32,640 21,515 66 %
Management fee income 26,212 27,867 (1,655) (6) %
Fee-for-services, net 9,434 12,059 (2,625) (22) %
Other income 4,194 3,753 441 12 %
Total revenue 510,397 381,867 128,530 34 %
Operating expenses
Cost of services 402,106 315,925 86,181 27 %
General and administrative expenses 39,660 30,031 9,629 32 %
Depreciation and amortization 14,004 13,793 211 2 %
Provision for doubtful accounts — (1,363) 1,363 (100) %
Impairment of intangibles — 1,994 (1,994) (100) %
Total expenses 455,770 360,380 95,390 26 %
Income from operations 54,627 21,487 33,140 154 %
Other income (expense)
Income from equity method investments 3,291 1,162 2,129 183 %
Gain on sale of equity method investment 99,647 — 99,647
Interest expense (8,007) (1,350) (6,657) 493 %
Interest income 2,544 1,305 1,239 95 %
Other income 1,514 2,832 (1,318) (47) %
Total other income, net 98,989 3,949 95,040 *
Income before provision for income taxes 153,616 25,436 128,180 *
Provision for income taxes 44,204 6,483 37,721 *
Net income 109,412 18,953 90,459 477 %
Net income attributable to noncontrolling interests 81,603 11,564 70,039 *
Net income attributable to Apollo Medical Holdings, Inc. $ 27,809 $ 7,389 $ 20,420 276 %


	Nine Months Ended September 30,
	2021		2020		$ Change	% Change
Revenue
Capitation, net	$	438,350	$	416,402	21,948	5	%
Risk pool settlements and incentives	94,146		54,155		39,991	74	%
Management fee income	26,345		26,212		133	1	%
Fee-for-services, net	14,968		9,434		5,534	59	%
Other income	5,006		4,194		812	19	%
Total revenue	578,815		510,397		68,418	13	%

Operating expenses
Cost of services, excluding depreciation and amortization	424,303		402,106		22,197	6	%
General and administrative expenses	45,476		39,660		5,816	15	%
Depreciation and amortization	13,105		14,004		(899)	(6)	%

Total expenses	482,884		455,770		27,114	6	%

Income from operations	95,931		54,627		41,304	76	%

Other income
(Loss) income from equity method investments	(3,680)		3,291		(6,971)	(212)	%
Gain on sale of equity method investment	2,193		99,647		(97,454)	(98)	%
Interest expense	(4,343)		(8,007)		3,664	(46)	%
Interest income	1,331		2,544		(1,213)	(48)	%
Unrealized gain on investments	22,826		—		22,826	100	%
Other (expense) income	(14,080)		1,514		(15,594)	*
Total other income, net	4,247		98,989		(94,742)	(96)	%

Income before provision for income taxes	100,178		153,616		(53,438)	(35)	%

Provision for income taxes	31,575		44,204		(12,629)	(29)	%

Net income	68,603		109,412		(40,809)	(37)	%

Net income attributable to noncontrolling interest	8,515		81,603		(73,088)	(90)	%

Net income attributable to Apollo Medical Holdings, Inc.	$	60,088	$	27,809	32,279	116	%

* Percentage change of over 500%

Net Income Attributable to Apollo Medical Holdings, Inc.

Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended September 30, ~~2020,~~2021, was ~~$16.7~~$34.3 million, as compared to ~~$3.7~~$16.7 million for the same period in ~~2019,~~2020, an increase of ~~$13.0~~$17.6 million.

Our net income attributable to Apollo Medical Holdings, Inc. for the nine months ended September 30, ~~2020,~~2021, was ~~$27.8~~$60.1 million, as compared to ~~$7.4~~$27.8 million for the same period in ~~2019,~~2020, an increase of ~~$20.4~~$32.3 million.

~~Table of Contents~~

The increase in net income attributable to Apollo Medical Holdings, Inc. for the three and nine months ended September 30, 2020, was primarily driven by the completion of a series of transactions with APC as further described in Note 1 to our financial statements above, which resulted in preferred, cumulative dividends from APC being allocated to AP-AMH and the results of operations as described below.

Physician Groups and Patients

As of September 30, ~~2020~~2021 and ~~2019,~~2020, we managed a total of 1412 and 1214 groups of affiliated physicians, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.1 million and ~~1.0~~1.1 million, respectively. The increase was attributable to management services agreements we entered into with independent practice associations, Community Family Care Medical Group IPA, Inc. ("CFC") and Beverly Alliance IPA dba Beverly Alianza IPA, which contributed 0.1 million new members.

Revenue

Our revenue for the three months ended September 30, ~~2020,~~2021, was ~~$180.1~~$227.1 million, as compared to ~~$156.1~~$180.1 million for the three months ended September 30, ~~2019,~~2020, an increase of ~~$24.0~~$47.0 million, or ~~15%~~26%. The increase in revenue was primarily attributable to the following:

(i) Capitation revenue increased by approximately ~~$4.2~~$14.0 million driven primarily by ~~the acquisition of Accountable Health Care on August 30, 2019 and organic~~membership growth at APC ~~which contributed additional capitation revenue of approximately $6.5 million~~ and $6.7 million, respectively. This increase was offset with a slight decrease in capitation revenue due to timing of $8.0 million of APAACO capitation revenue and the related claims expenditures incurred and $1.0 million of retroactive adjustments decreasing membership at Alpha Care.

(ii) Risk pool settlement and incentive revenue increased by ~~$19.6~~$29.0 million ~~primarily due to~~driven by an incentive payment received from one of our payor partners totaling approximately $14.6 million, increased risk pool revenue of $12.4 million driven by reduced utilization at ApolloMed’s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, as these revenues from ApolloMed’s partner hospitals reflect a 15-18 month lag, and a $2.0 million increase in the shared savings settlement earned ~~related to the settlement of the 2019~~from ApolloMed’s participation in an ACO for performance year 2020.

(iii) Fee for service increased by approximately $3.5 million driven by the consolidation of ~~$19.8~~Sun Labs beginning August 2021 which contributed $2.0 million and increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19 of $1.5 million.

Our revenue for the nine months ended September 30, ~~2020~~2021, was ~~$510.4~~$578.8 million, as compared to ~~$381.9~~$510.4 million for the nine months ended September 30, ~~2019,~~2020, an increase of ~~$128.5~~$68.4 million, or ~~34%~~13%. The increase in revenue was primarily attributable to the following:

(i) Capitation revenue increased by approximately ~~$110.9~~$21.9 million primarily due to our acquisitions of Alpha Care on May 31, 2019 and Accountable Health Care on August 30, 2019, which contributed additional revenue of approximately $52.0 million and $30.8 million, respectively, in addition to organicdriven by membership growth at APC ~~of $11.2 million due to increased~~and Alpha Care and higher average capitation ~~rates. Further, APAACO generated~~rate at APC. APC and Alpha Care contributed additional capitation revenue of approximately ~~$16.2~~$29.9 million ~~for the nine months ended September 30, 2020 as compared September 30, 2019,~~and $5.7 million, respectively. This was offset with a decrease in capitation revenue at APAACO and Accountable Health Care of $4.5 million and $9.1 million, respectively. The decrease in revenue at APAACO was due to timing of claims expenditures incurred and the ~~delayed start~~decrease at Accountable Health Care was a result of ~~the 2019 APAACO performance year which began on April 1, 2019 and resulted in less revenue in early 2019.~~membership reductions.

(ii) Risk pool settlement and incentive revenue increased by ~~$21.5~~$40.0 million ~~primarily due to~~driven by reduced utilization at ApolloMed’s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, as these revenues from ApolloMed’s partner hospitals reflect a 15-18 month lag, the reduced utilization resulted in increased risk pool revenue of $23.4 million. The remaining increase was driven by an incentive payment received from one of our payor partners totaling approximately $14.6 million and a $2.0 million increase in the shared savings settlement earned ~~related to the settlement of the 2019~~from ApolloMed’s participation in an ACO for performance year of $19.8 million and the continued refinement of the assumptions used to estimate the amount of net surplus expected to be received from the affiliated hospitals’ risk pools. Our estimated risk pool receivable is calculated based on reports received from our hospital partners and on management’s estimate of the Company’s portion of any estimated risk pool surpluses for which payments have not been received. The actual risk pool surpluses are settled approximately 18 months later.2020.

(iii) ~~Management fee income decreased~~Fee for service increased by $1.7 million mainly due to our acquisition of Accountable Health Care, which reduced management fee income by $5.7 million, a decrease of $0.5 million in management fees due to timing of membership adjustments at LMA and a reduction in hospitalist stipend of $1.0 million as we focused our resources to our core hospital partners. This decrease was offset by management fee income ofapproximately $5.5 million for the nine months ended September 30, 2020 generated from the management services agreement we entered into with CFC which became effective on January 1, 2020, and Beverly Alianza IPA, which became effective on July 1, 2020.

~~(iv) Fee-for-service revenue decreased by $2.6~~ million due to ~~reduced procedures performed at~~increased visits to our surgery ~~centers~~ and heart ~~center~~centers, which were partially closed in the prior year due COVID-19 of $3.5 million and $2.0 million as a result of the ~~extended COVID-19 outbreak.~~

~~Table~~consolidation of ~~Contents~~

Sun Labs beginning August 2021.

Cost of Services, excluding depreciation and amortization

Expenses related to cost of services for the three months ended September 30, ~~2020,~~2021, were ~~$121.8~~$147.5 million, as compared to ~~$131.1~~$121.8 million for the same period in ~~2019, a decrease~~2020, an increase of ~~$9.3 million, or 7%.~~$25.7 million. The overall ~~decrease~~increase was primarily due to ~~a $10.3 million decrease~~an increase in medical claims, capitation, and other health services expenses resulting from reduced elective procedures as a result of the COVID-19 outbreak offset by the $1.0 million increase in payroll expenses related to an increase in the number of employees related to the growth in both the depth and breadth of our operations in multiple markets.expenses.

Expenses related to cost of services for the nine months ended September 30, ~~2020,~~2021, were ~~$402.1~~$424.3 million, as compared to ~~$315.9~~$402.1 million for the same period in ~~2019,~~2020, an increase of ~~$86.2 million, or 27%.~~$22.2 million. The overall increase was primarily due to ~~a $90.6 million~~an increase in medical claims, capitation, and other health services expenses, primarily driven by the acquisition of Alpha Care, Accountable Health Care and AMG, in addition to increased costs at APAACO for the nine month period ended September 30, 2020, as compared to the same period in 2019 due to the delayed start of the 2019 APAACO performance year and a $5.2 million increase in payroll expenses related to an increase in the number of employees related to the growth in both the depth and breadth of our operations in multiple markets. The increased costs were offset by a net decrease of $10.0 million in bonus payments made to providers for the nine months ended September 30, 2020 as compared to the bonus payments made to providers during the same period in 2019.expenses.

General and Administrative Expenses

General and administrative expenses for the three months ended September 30, ~~2020,~~2021, were ~~$16.3~~$21.8 million, as compared to ~~$8.0~~$16.3 million for the same period in ~~2019,~~2020, an increase of ~~$8.3~~$5.5 million, or ~~105%~~34%. The increase was primarily due to ~~a $4.4 million~~an increase in bonus paid ~~to ACO~~certain physicians driven by the increase in shared savings earned related to the settlement of the ~~2019~~2020 ACO performance year and a reduction in professional services costs of $2.0 million specific to the three months ended September 30, 2019. The remaining increase was primarily due to continued growth in the depth and breadth of our operations in multiple markets.year.

General and administrative expenses for the nine months ended September 30, ~~2020~~2021, were ~~$39.7~~$45.5 million, as compared to ~~$30.0~~$39.7 million for the same period in ~~2019,~~2020, an increase of ~~$9.7~~$5.8 million, or ~~32%~~15%. The increase is primarily due to costs incurred as a ~~$4.4 million~~result of the execution of the Amended Credit Facility agreement and an increase in bonus paid to ~~ACO~~certain physicians driven

by the increase in shared savings earned related to the settlement of the ~~2019~~2020 ACO performance ~~year and~~year. This is partially offset by a reduction in consulting and professional ~~services~~ costs as a result of ~~$2.0 million specific to the three months ended September 30, 2019. The remaining increase was primarily due to~~efficiencies gained from our continued ~~growth in the depth and breadth~~development of our ~~operations in multiple markets.~~in-house technology platform of approximately $1.0 million and the elimination of rent expense for properties leased by MPP, ZLL, and AMG Properties as a result of the Company's acquisition of these entities.

Depreciation and Amortization

Depreciation and amortization expenses for the three months ended September 30, ~~2020~~2021, were $4.7 million, as compared to ~~$4.9~~$4.7 million for the same period in ~~2019.~~2020. This amount includes depreciation of property and equipment and the amortization of intangible assets.

Depreciation and amortization expenses for the nine months ended September 30, ~~2020~~2021, were ~~$14.0~~$13.1 million, as compared to ~~$13.8~~$14.0 million for the same period in ~~2019.~~2020. This amount includes depreciation of property and equipment and the amortization of intangible assets.

~~Provision for Doubtful Accounts~~

For the nine months ended September 30, 2019, we released reserves related to certain management fees in the amount of approximately $1.4 million as collectability of the outstanding amount was no longer in doubt. These reserves were related to various preacquisition obligations of Accountable Health Care and were no longer necessary as a result of our acquisition of Accountable Health Care.

~~Impairment of Intangibles~~

For the three and nine months ended September 30, 2019, we recorded impairment of intangible assets totaling $2.0 million related to Medicare licenses obtained as part of the 2017 merger between NMM and ApolloMed. We no longer utilize the licenses and will not receive future economic benefits therefrom.

~~Table of Contents~~

(Loss) Income from Equity Method Investments

Income from equity method investments for the three months ended September 30, ~~2020,~~2021, was ~~$0.4~~$0.1 million, as compared to income from equity method investments of ~~$2.1~~$0.4 million for the same period in ~~2019,~~2020, a decrease of ~~$1.7~~$0.3 million. The decrease was primarily due to ~~a $1.8 million gain recognized related to~~ our investment in ~~Accountable Health Care resulting~~LMA. The Company incurred a loss of $0.3 million from ~~our acquisition in August 2019.~~LMA as a result of increased claims expense for the three months ended September 30, 2021.

~~Income~~Loss from equity method investments for the nine months ended September 30, ~~2020,~~2021, was ~~$3.3~~$3.7 million, as compared to income from equity method investments of ~~$1.2~~$3.3 million for the same period in ~~2019, an increase~~2020, a decrease of ~~$2.1~~$7.0 million. The ~~increase~~decrease was ~~primarily~~partially due to ~~equity earnings from our investment in UCI of $3.7 million, offset by equity loss from our investment in 531 W. College of $0.4 million, as~~ the property is in redevelopment to a multi-specialty clinic, for the nine months ended September 30, 2020. This is compared with equity earnings from our investments in UCI, DMG, and PMIOC of $6.1 million, $0.7 million, and $0.2 million, respectively, offset with equity losses from our investments in LMA's IPA line of business and Accountable Health Care of $2.8 million and $2.7 million, respectively, and the recognition of an impairment loss of $0.3 million related to our investment in PASC for the nine months ended September 30, 2019.

~~Gain on Sale of Equity Method Investments~~

~~Gain on~~ sale of ~~equity method investments for~~UCI in April 2020. For the nine months ended September 30, 2020, ~~was $99.6~~UCI contributed equity earnings of $3.6 million. The additional decrease is from our investment in LMA. For the nine months ended September 30, 2021, the Company incurred a loss of $4.7 million ~~resulting~~ from LMA as a result of increased claims expense as compared to equity earnings of $1.8 million for the ~~sale of UCI which closed on April~~nine months ended September 30, 2020.

Interest Expense

Interest expense for the three months ended September 30, ~~2020,~~2021, was ~~$2.5~~$1.0 million, as compared to ~~$0.8~~$2.5 million for the same period in ~~2019, an increase~~2020, a decrease of ~~$1.7~~$1.5 million. The ~~increase~~decrease in interest expense for the three months ended September 30, 2021 was ~~primarily~~ due to ~~the credit facility we secured in~~lower interest rates and lower outstanding debt balance at September ~~2019~~30, 2021 as compared to ~~fund growth, primarily through acquisitions.~~September 30, 2020.

Interest expense for the nine months ended September 30, ~~2020,~~2021, was ~~$8.0~~$4.3 million, as compared to ~~$1.4~~$8.0 million for the same period in ~~2019, an increase~~2020, a decrease of ~~$6.6~~$3.7 million. The ~~increase~~decrease in interest expense for the nine months ended September 30, 2021, was primarily due to the ~~new credit facility we secured~~Company refinancing their Credit Facility to the Amended Credit Facility in June 2021 which resulted in lower interest rates for the nine months ended September ~~2019~~30, 2021, as compared to ~~fund growth, primarily through acquisitions.~~the same periods in 2020.

Interest Income

Interest income for the three and nine months ended September 30, ~~2020,~~2021, was ~~$0.8~~$0.4 million and ~~$2.5~~$1.3 million, respectively, as compared to ~~$0.5~~$0.8 million and ~~$1.3~~$2.5 million, respectively, for the three and nine months ended September 30, ~~2019.~~2020. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.

~~Other Income~~Unrealized (Loss) Gain on Investments

~~Other income for~~For the three and nine months ended September 30, ~~2020, was $0.1~~2021 we recognized an unrealized loss of $60.9 million and ~~$1.5~~unrealized gain of $22.8 million, respectively. The unrealized loss and gain is driven by fluctuations in the stock price of a payor partner in which we hold shares in. These shares are recorded as marketable securities and deemed an Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc.

Other Income (Expense)

Other income for the three months ended September 30, 2021, was $0.5 million, as compared to ~~other income of $2.6~~$0.1 million ~~and $2.8 million, respectively,~~ for the same ~~periods~~period in ~~2019.~~2020, an increase of $0.4 million.

Other expense for the nine months ended September 30, 2021, was $14.1 million, as compared to income of $1.5 million for the same period in 2020, a decrease of $15.6 million. The decrease ~~in other income~~ was primarily due to the ~~assumption~~write-off of ~~a loan receivable as a~~certain beneficial interest related to the UCI disposition totaling $15.7 million. The beneficial interest was an Excluded Assets that was deemed solely for the benefit of APC and its shareholders. As such, the write-off did not result ~~of the Accountable Health Care acquisition~~ in ~~August 2019.~~any impact to net income attributable to Apollo Medical Holdings, Inc.

(Benefit from) Provision for Income ~~Tax~~Taxes

~~Income tax expense~~Benefit from provision for income taxes was ~~$10.8~~$0.1 million for the three months ended September 30, ~~2020,~~2021, as compared to ~~$3.7~~provision for income taxes of $10.8 million for the same period in ~~2019. The increase in tax expense~~2020. This was due to ~~increased~~a decrease in pre-tax income infor the three months ended September 30, ~~2020,~~2021, period as compared to the same period in ~~2019,~~2020, as described above.

~~Income tax expense~~Provision for income taxes was ~~$44.2~~$31.6 million for the nine months ended September 30, ~~2020,~~2021, as compared to ~~$6.5~~$44.2 million for the same period in ~~2019.~~2020. The ~~increase~~decrease in ~~tax expense~~provision for income taxes was due to ~~increased~~a decrease in pre-tax income infor the nine months ended September 30, ~~2020~~2021, period as compared to the same period in ~~2019,~~2020, as described above.

Net (Loss) Income Attributable to Noncontrolling Interests

Net loss attributable to noncontrolling interests for the three months ended September 30, 2021, was $39.7 million, as compared to net income attributable to noncontrolling interests ~~was $8.7 million~~ for the three months ended September 30, 2020 ~~compared to $7.0~~of $8.7 million, ~~for the same period in 2019, an increase~~respectively, a decrease of ~~$1.7~~$48.4 million. The ~~increase~~decrease was primarily driven by ~~the increased income generated~~an unrealized loss resulting from a decreased fair value in ~~the current period which resulted in additional income allocated~~our marketable securities related to ~~the noncontrolling interest.~~

~~Table~~shares held of ~~Contents~~

a payor partner.

Net income attributable to noncontrolling interests ~~was $81.6 million~~ for the nine months ended September 30, 2021 and September 30, 2020, ~~compared to $11.6~~was $8.5 million ~~for the same period in 2019, an increase~~and $81.6 million, respectively, a decrease of ~~$70.0~~$73.1 million. The ~~increase~~decrease was primarily ~~due to of~~driven by the sale of UCI which was completed in April ~~2020 where the gain remains strictly with the APC Excluded Assets and increased income generated in the current period which resulted in additional income allocated to the noncontrolling interest.~~2020.

~~2020~~2021 Guidance

~~We are~~ApolloMed is raising ~~our~~its full-year 2021 guidance, previously disclosed ~~full-year 2020 net income, Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), and adjusted EBITDA guidance~~on August 5, 2021, as a result of its continued organic growth and increased risk pool settlements and incentives revenue as a ~~net~~result of reduced utilization at ApolloMed’s partner hospitals in 2020 during the COVID-19 pandemic and a shared savings settlement of ~~$13.3~~$21.8 million ~~(net of provider bonus) earned in the third quarter of 2020 as a reward~~ from ~~participating~~ApolloMed's participation in an ~~attribution-based risk sharing model. ApolloMed is raising its previously disclosed full-year~~Accountable Care Organization ("ACO") for the 2020 net income, Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), and adjusted EBITDA guidance as a result of a net shared savings settlement of $13.3 million (net of provider bonus) earned in the third quarter of 2020 as a reward from participating in an attribution-based risk sharing model.performance year. Net income and EBITDA include the impact of ~~the gain of approximately $99.6 million related to the sale of Universal Care Acquisition Partners, LLC's ("UCAP") 48.9%~~APC investment in ~~Universal Care, Inc. ("UCI")~~a payor partner, which completed an initial public offering to ~~Bright Health Company of California, Inc. ("Bright"), which closed on April 30, 2020.~~become a publicly traded company in June 2021. As ~~UCI was included in Excluded Assets and remained~~APC’s investment is an excluded asset solely for the benefit of ~~ApolloMed's affiliate, Allied Physicians of California, a Professional Medical Corporation, ("APC")~~APC and its shareholders, ~~the gain on sale does~~any gains or losses as a result of this investment do not affect the net income attributable to ApolloMed and adjusted EBITDA attributable to ApolloMed.

~~Our~~ The November 4, 2021 revised net income and EBITDA guidance ranges assume a stock price of the payor partner of $8.49. These assumptions are based on the Company’s existing business, current view of existing market conditions, and assumptions for the year ending December 31, ~~2020, is~~2021.


(in millions)	2021 Guidance Range				2021 Guidance Range
	(as of August 5, 2021)				(as of November 4, 2021)
	Low		High		Low		High
Total revenue	$	700.0	$	720.0	$	751.5	$	758.5
Net income	$	56.0	$	66.0	$	81.0	$	83.5
Net income attributable to ApolloMed	$	48.0	$	58.0	$	71.5	$	73.5
Earnings per share - diluted	*		*		$	1.58	$	1.62
EBITDA	$	100.0	$	119.0	$	139.0	$	143.0
Adjusted EBITDA	$	120.5	$	130.5	$	168.5	$	170.5

*Range was not previously provided as ~~follows:~~of August 5, 2021.

•~~Maintaining total revenue between $665.0 million and $675.0 million due to impact of COVID-19 on FFS revenue,~~

•~~Raising net income from a range of $100.0 million to $110.0 million (disclosed on May 27, 2020) to a range of $110.0 million to $120.0 million,~~

•~~Raising EBITDA from a range of $155.0 million to $167.0 million (disclosed on May 27, 2020) to a range of $182.0 million to $194.0 million, and~~

•~~Raising adjusted EBITDA from a range of $75.0 million to $90.0 million (disclosed on March 12, 2020) to a range of $97.0 million to $112.0 million.~~

See ~~"Guidance~~“Guidance Reconciliation of Net Income to EBITDA and adjusted ~~EBITDA~~"EBITDA” and ~~"Use~~“Use of Non-GAAP Financial ~~Measures~~"Measures” for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See ~~"Forward-Looking Statements"~~“Forward-Looking Statements” within this Quarterly Report on Form 10-Q.

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA
Year Ending
December 31, 2020
(in thousands)
Low High
Net income(1)
$ 110,000 $ 120,000
     Depreciation and amortization 19,000 20,000
     Provision for income taxes 46,000 47,000
     Interest expense 10,000 11,000
     Interest income (3,000) (4,000)
EBITDA(1)
182,000 194,000
     Income from equity method investments (2)
(100,000) (99,000)
     EBITDA adjustment for recently acquired IPAs 15,000 17,000
Adjusted EBITDA $ 97,000 $ 112,000

~~(1)~~ Net income and EBITDA include the gain on sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI was included in Excluded Assets and as such remained solely for the benefit of APC and its shareholders. As such, any proceeds or gain on sale has not affected the net income and adjusted EBITDA attributable to ApolloMed.

~~Table of Contents~~

~~(2)~~ Income from equity method investments is mainly attributed to the sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI was included in Excluded Assets and as such remained solely for the benefit of APC and its shareholders. As such, any proceeds or gain on sale has not affected the net income and adjusted EBITDA attributable to ApolloMed.


Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA
	2021 Guidance Range				2021 Guidance Range
	(as of August 5, 2021)				(as of November 4, 2021)
(in thousands)
	Low		High		Low		High
Net income	$	56,000	$	66,000	$	81,000	$	83,500
Interest expense	6,000		8,400		5,000		6,000
Interest income	(1,500)		(2,400)		(1,200)		(1,700)
Provision for income taxes	24,000		29,000		37,000		38,000
Depreciation and amortization	15,500		18,000		17,200		17,200
EBITDA	100,000		119,000		139,000		143,000

Income (loss) from equity method investments	3,500		(500)		(3,900)		(3,600)
Investment in payor partner	(9,000)		(9,000)		—		—
Provider bonus payments	6,000		6,000		8,900		8,900
Net loss adjustment for recently acquired IPAs	20,000		15,000		24,500		22,200
Adjusted EBITDA	$	120,500	$	130,500	$	168,500	$	170,500

Use of Non-GAAP Financial Measures

This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with ~~GAAP~~U.S. generally accepted accounting principles (“GAAP”) is net (loss) income. These measures are not in accordance with, or an alternative to, ~~U.S. generally accepted accounting principles, (“GAAP”),~~GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income from equity method investments, provider bonuses, impairment of intangibles, provision of doubtful accounts, and other income earned that is not related to the ~~Company's~~Company’s normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired.

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ~~ApolloMed's~~the Company’s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation from, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

Liquidity and Capital Resources

Cash, cash equivalents and investment in marketable securities at September 30, ~~2020,~~2021, totaled ~~$284.4~~$333.3 million as compared to ~~$219.7~~$261.2 million at December 31, ~~2019.~~2020. Working capital totaled ~~$235.2~~$310.5 million at September 30, ~~2020,~~2021, as compared to ~~$223.7~~$223.6 million at December 31, ~~2019,~~2020, an increase of ~~$11.5~~$86.9 million, or 5%39%.

We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, and fee-for-service reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.

Our cash, cash equivalents and restricted cash increased by ~~$62.8~~$10.8 million from ~~$104.0~~$194.0 million at December 31, ~~2019,~~2020, to ~~$166.8~~$204.8 million at September 30, ~~2020.~~2021. Cash provided by operating activities ~~during~~for the nine months ended September 30, ~~2020,~~ 2021,

was ~~$48.8~~$82.5 million, as compared to ~~$10.1~~cash provided by operating activities of $48.8 million for the nine months ended September 30, ~~2019.~~2020. The increase in cash provided by operating activities was primarily driven by increase in earnings adjusted for non-cash items of approximately $89.4 million for the nine months ended September 30, 2021 compared to $17.9 million for the nine months ended September 30, 2020 and timing of ~~our~~ working capital accounts. For the nine months ended September 30, ~~2020,~~2021, prepaid expenses and other current assets and accounts payable and accrued expenses resulted in cash inflow of $19.4 million, while receivable, net, receivable, net - related parties, ~~and~~ other receivable, ~~resulted in net cash inflow of $12.6 million as compared to cash outflow of $6.0 million for the same period in 2019, while accounts payable and accrued expenses~~medical liabilities, and income taxes payable resulted in ~~net cash inflow of $24.3 million as compared to~~ cash outflow of ~~$5.4 million for~~$24.5 million. For the nine months ended September 30, 2020, receivable, net - related parties, other receivables, accounts payable and ~~September 30, 2019, respectively. This was offset with~~accrued expenses, fiduciary accounts payable, and income taxes payable resulted in cash inflow of $45.8 million, while receivable, net, prepaid expenses and other current assets, other assets, and medical liabilities resulted in a ~~non~~ cash ~~adjustment to net income related to deferred taxes~~outflow of ~~$6.1 million for~~$15.4 million.

Cash used in investing activities during the nine months ended September 30, ~~2020 as~~2021, was $22.5 million, primarily due to purchases of property and equipment of $16.4 million, payments for business acquisition of $2.6 million, funding for an equity method investment of $13.4 million, and purchase of marketable securities of $1.0 million. The cash used in investing activities was partially offset by cash received from consolidation of Tag 8 of $3.3 million, proceeds from sale of equity method investment of $6.4 million, and proceeds from sale of marketable securities of $1.1 million. This is compared to ~~$0.2 million for the same period in 2019.~~

~~Cash~~cash provided by ~~from~~ investing activities during the nine months ended September 30, 2020, ~~was~~of $66.4 million, which was primarily due to proceeds received related to the sale of UCI totaling $52.7 million and loan receivables of $16.5 million offset with cash outflow related to the purchase of marketable securities of $1.8 million, funding for an equity method investment of $0.5 million, and capital expenditures (mainly purchases of property and equipment) of $0.5 million. This is compared to cash used of $60.4 million for the nine months ended September 30, 2019 due to payments for business acquisition of $49.4 million, advances on loans receivable of $7.4 million, funding for an equity method investment of $3.0 million, and capital expenditures of $0.8 million offset with dividends received of $0.2 million.

~~Table of Contents~~

Cash used in financing activities during the nine months ended September 30, ~~2020,~~2021, was ~~$52.3~~$49.2 million as compared to cash ~~provided by~~used in financing activities of ~~$173.7~~$52.3 million for the nine months ended September 30, ~~2019.~~2020. Cash used for the nine months ended September 30, 2021 was primarily due to repayment of long-term debt of $238.3 million, dividend payment of $31.1 million, and repurchase of shares of $5.7 million. The cash used in financing activities was partially offset by a drawdown of $180.0 million on the Amended Credit Facility, proceeds from sale of shares of $40.1 million, and proceeds from the exercise of options and warrants of $6.6 million. This is compared to cash used in financing activities for the nine months ended September 30, 2020 of $52.3 million which was due to the payments of dividends totaling $50.1 million, repayment on our term loan totaling $7.1 million and repurchase of shares of $1.6 million, offset with proceeds from exercise of stock options and warrants of $6.6 million. This is compared to cash provided by for the nine months period ended September 30, 2019 due to proceeds from borrowings on our line of credit of $289.6 million, proceeds from the exercise of stock options and warrants of $2.4 million and proceeds from common stock offering of $0.8 million offset with payments of dividends, repayments on our bank loan and lines of credit and cost of debt and equity issuance totaling $60.7 million, $52.6 million and $5.6 million respectively.

Excluded Assets

In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement, ~~clarifying~~which clarified the term ~~Excluded Assets.~~“Excluded Assets”. “Excluded Assets” means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of ~~the Company~~APC that are not Healthcare Services Assets (as defined in the purchase agreement), including ~~the Company’s~~APC’s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii).

The Excluded Assets as of September 30, 2021, are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. As of September 30, 2021 and December 31, 2020, the Excluded Assets balance consisted of the following (in thousands):

September 30, 2020 December 31, 2019
Cash and cash equivalents $ 23,957 $ 23,013
Investment in marketable securities 118,187 116,853
Land, property and equipment, net 5,096 5,137
Investments in other entities - equity method 17,070 18,360
Total Excluded Assets $ 164,310 $ 163,363

~~Table~~


	September 30, 2021		December 31, 2020

Cash and cash equivalents	$	31,701	$	38,773
Investment in marketable securities (1)	124,569		66,534
Land, property, and equipment, net	44,014		24,466
Loan receivable – related parties	4,050		4,145
Investments in other entities – equity method	24,581		25,847
Investments in privately held entities	—		36,179
Other receivable	824		15,723
Other liabilities	(1,341)		—
Long-term debt	(7,452)		(7,580)

Total Excluded Assets	$	220,946	$	204,087

(1) The increase in investment in marketable securities is due to a 1-to-3 conversion of ~~Contents~~a payor partner’s preferred shares to common stock as a result of the payor partner becoming a public company in June 2021. Prior to the payor partner becoming a public company, the preferred shares were recognized as investments in privately held entities.

Credit Facilities

The Company’s ~~credit facility~~debt balance consisted of the following (in thousands):


	September 30, ~~2020~~2021

~~Term loan A~~Revolver Loan	$	~~180,500~~180,000
~~Revolver loan~~Real Estate Loans	~~60,000~~7,447
Construction Loan	77
Total debt	~~240,500~~187,524

Less: Current portion of debt	~~(9,500)~~(207)
Less: Unamortized financing costs	~~(4,949)~~(4,504)

Long-term debt	$	~~226,051~~182,813

The following ~~table presents scheduled~~are the future commitments of the Company’s ~~credit facility is to be as follows~~debt for the years ending December 31 (in thousands):


		Amount			Amount
2020 (excluding the nine months ended September 30, 2020)		$	2,375
2021		10,688
2021 (excluding the nine months ended September 30, 2021)				2021 (excluding the nine months ended September 30, 2021)	$	55
2022	2022	14,250		2022	285
2023	2023	15,437		2023	215
2024	2024	197,750		2024	222
2025 and thereafter				2025 and thereafter	186,747

Total	Total	$	240,500	Total	$	187,524

Credit Agreement

~~In September 2019,~~On June 16, 2021, the Company entered into ~~a secured~~an amended and restated credit agreement (the ~~“Credit Agreement,”~~“Amended Credit Agreement” and the credit facility thereunder, the ~~"Credit Facility"~~“Amended Credit Facility”) with Truist Bank, ~~(formerly known as SunTrust Bank),~~ in its ~~capacity~~capacities as administrative agent for the lenders (in such capacity, the “Agent”), ~~as a lender, an issuer of letters of credit and as~~issuing bank, swingline lender and ~~Preferred Bank,~~a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the “Lenders”), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as ~~lenders (the “Lenders”). In connection with the closing of the Credit Agreement,~~Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, ~~its subsidiary, NMM,~~certain Lenders and the Agent, entered into a Guaranty and Security Agreement (the “Guaranty and Security Agreement”), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement.in its entirety.

The Amended Credit Agreement provides for a five-year revolving credit facility (“Revolver Loan”) to the Company of ~~$100.0~~$400.0 million, ~~(“Revolver Loan”),~~ which includes a letter of credit ~~subfacility~~sub-facility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (“Term Loan A”). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and ~~for the following three fiscal quarters thereafter is $4.8~~a swingline loan sub-facility of $25.0 million. The ~~remaining principal payment on the term loan is due on September 11, 2024.~~

The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and to provide for working capital needs ~~capital expenditures~~ and other general corporate purposes.

~~Table~~ Under the Amended Credit Agreement, the terms and conditions of ~~Contents~~

the Guaranty and Security Agreement remain in effect.

Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company’s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (“LIBOR”), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company’s leverage ratio. As of September 30, 2020, the interest rate on Term Loan A for the 2020 commitment and future commitments was 2.72% and 2.77%, respectively. As of September 30, 2020, the interest rate on the Revolver Loan was 2.77%. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company’s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.

~~The~~Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis.

Covenant Ratios (1)

Requirement

September 30, ~~2020~~2021

Consolidated leverage ratio

Less than 3.75 to 1.00

~~1.79~~1.06

Consolidated interest coverage ratio

Greater than 3.25 to 1.00

~~10.33~~25.55

(1) All covenant ratio titles utilize terms as defined in the respective debt agreements.

~~Pursuant~~Refer to ~~the Guaranty~~Note 9 – “Credit Facility, Bank Loans, and ~~Security Agreement, the Company and NMM have granted the Lenders a security interest~~Lines of Credit” to our consolidated financial statements under Item 1 in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.

~~Table of Contents~~

~~The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default~~this Quarterly Report on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cashForm 10-Q for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH’s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company’s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.

Deferred Financing Costs

Effective Interest Rate

The Company’s average effective interest rate on its total debt during the nine months ended September 30, 2021 and 2020, were 2.15% and ~~2019, was~~ 3.79% ~~and 1.31%~~, respectively. Interest expense in the consolidated statements of ~~income~~operations included amortization of deferred debt issuance costs for the three and nine months ended September 30, 2021 and 2020, ~~and 2019,~~ of ~~$0.3~~$0.2 million and ~~0.1~~$0.3 million, respectively, and ~~$1.0~~$0.9 million and ~~$0.1~~$1.0 million, respectively.

Real Estate Loans

On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase, APC assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively. Refer to Note 9 – “Credit Facility, Bank Loans, and Lines of ~~Credit – Related Party~~Credit” to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.

~~NMM Business~~

Construction Loan

~~On June 14, 2018, NMM amended its promissory note~~In April 2021, Tag 8 entered into a construction loan agreement with ~~Preferred~~MUFG Union Bank N.A. (“~~NMM Business Loan Agreement”~~Construction Loan”)~~, which provides for loan availability of~~ that allows Tag 8 to borrow up to ~~$20.0 million with~~$10.7 million. Tag 8 is a ~~maturity date of June 22, 2020. One of~~VIE consolidated by the ~~Company’s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September 1, 2018,~~Company. Refer to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October 31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal “prime rate,” plus 0.125%, or 5.625% as of December 31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amount outstanding as of June 30, 2019, of $5.0 million was fully repaid on September 11, 2019.

Note 9 – “Credit

6362

~~Table of Contents~~

~~On September 11, 2019, the NMM Business Loan Agreement, dated as~~Facility, Bank Loans, and Lines of ~~June 14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September 5, 2018, between NMM and Preferred Bank, as amended, were terminated~~Credit” to our consolidated financial statements under Item 1 in connection with the closing of the credit facility. Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of September 30, 2020, outstanding letters of credit totaled $8.2 million and the Company has $10.2 million available under the revolving credit facilitythis quarterly report on Form 10-Q for ~~letters of credit.~~

~~APC Business Loan~~

On June 14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June 22, 2020. This credit facility was subsequently amended on April 17, 2019, and June 11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December 31, 2020. On August 1, 2019, and September 10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC’s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal “prime rate,” plus 0.125%, or 3.375% and 4.875% as of September 30, 2020 and December 31, 2019, respectively. As of September 30, 2020 and December 31, 2019, there was no availability under this line of credit.additional information.

Intercompany Loans

Each of AMH, MMG, ~~BAHA,~~ AKM Medical Group, Inc. ~~("AKM"~~(“AKM”), SCHC, and ~~SCHC~~Bay Area Hospitalist Associates (“BAHA”) has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated ~~entities~~entity in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM’s obligation to make any advances automatically terminates ~~concurrently with~~upon the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).


						Nine Months Ended September 30, 2020													Nine Months Ended September 30, 2021
Entity	Entity	Facility		Interest Rate per Annum		Maximum Balance During Period		Ending Balance		Principal Paid During Period		Interest Paid During Period		Entity	Intercompany Credit Facility		Interest Rate per Annum		Maximum Balance During Period		Ending Balance		Principal Paid During Period		Interest Paid During Period
AMH	AMH	$	10,000	10	%	$	6,391	$	6,391	$	—	$	—	AMH	$	10,000	10	%	$	6,588	$	6,588	$	—	$	—
MMG	MMG	3,000		10	%	3,663		3,663		—		—		MMG	3,000		10	%	3,663		3,663		—		—
AKM	AKM	5,000		10	%	—		—		—		—		AKM	5,000		10	%	—		—		—		—
SCHC	SCHC	5,000		10	%	5,180		5,180		—		—		SCHC	5,000		10	%	5,362		5,362		—		—
BAHA	BAHA	250		10	%	4,066		3,945		—		—		BAHA	250		10	%	4,066		3,945		—		—
		$	23,250			$	19,300	$	19,179	$	—	$	—		$	23,250			$	19,679	$	19,558	$	—	$	—

~~Table of Contents~~

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 thereto. Please also refer to the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2019.~~2020.

New Accounting Pronouncements

See Note 2 to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.

Off-Balance Sheet Arrangements

As of September 30, ~~2020,~~2021, we had no off-balance sheet arrangements that are or have ~~or are~~been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Inflation

Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of September 30, ~~2020,~~2021, we had ~~$240.5~~$180.0 million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Credit Agreement bears interest at an annual rate equal to either, at the Company’s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of ~~2.00%~~1.25% to ~~3.00%~~2.5%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread of ~~1.00%~~0.25% to ~~2.00%~~1.5%, as determined on a quarterly basis based on the Company’s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR. In addition, as of September 30, 2021, Tag 8, a VIE consolidated by the Company, had $0.1 million in outstanding borrowings for the Construction Loan. Interest rate on the “Construction Loan” is equal to an index rate determined by the bank. Furthermore, as of September 30, 2021, APC had $7.4 million in outstanding borrowings for real estate loans related to ZLL, MPP, and AMG Properties (“Real Estate Loans”). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal Prime Rate, as quoted in the “Money Rates” column of The Wall Street Journal (Western edition) as determined by the Lender (the “Index”). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.500% per annum or more than the maximum rate allowed by applicable law. The Company ~~will pay fees~~has entered into interest rate swap agreements for ~~standby letters~~certain of ~~credit at an annual rate equal~~these agreements to ~~2.00%~~effectively convert its floating-rate debt to ~~3.00%, as determined on~~ a ~~quarterly basis based on~~fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company’s ~~leverage ratio, plus facing fees and standard fees payable to~~floating-rate debt, thus reducing the ~~issuing bank~~impact of interest rate changes on ~~the respective letter of credit.~~future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loan, and Real Estate Loans would have increased or decreased our interest expense for the three months ended September 30, ~~2020,~~2021, by ~~$2.4~~$1.9 million.

~~Table of Contents~~

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of September 30, ~~2020,~~2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of September 30, ~~2020,~~2021, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the ~~Securities and Exchange Commission~~SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Control ~~Over~~over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under Exchange Act) during our third fiscal quarter of ~~2020~~2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

6665

~~Table of Contents~~

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and ~~proceedings, most of which involve claims of medical malpractice related to medical services that are provided by our affiliated hospitalists.~~proceedings. Many of the Company’s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding which ~~in the opinion of~~ management ~~is expected~~expects to, individually or in the aggregate, have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company’s financial condition, cash flows, or results of operations.

ITEM 1A. RISK FACTORS

Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020, filed with the SEC on March ~~16, 2020.~~15, 2021. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual ~~Report except as described below.~~Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.

These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company’s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

The current outbreak of the novel coronavirus disease, or COVID-19, or the future outbreak of any other highly infectious or contagious diseases, could adversely impact or cause disruption to our business, financial condition and results of operations.

An epidemic outbreak or other public health crisis nationally or in the markets where we operate could adversely affect our operations and financial results. For example, the recent outbreak of COVID-19, the World Health Organization declared a pandemic on March 11, 2020, and which the U.S. declared a national emergency on March 13, 2020, has caused governments and the private sector globally to take a number of drastic precautionary measures to contain the spread of the coronavirus, including the restriction and suspension of in-person classes at schools, colleges and universities, the cancellation of public events and other nonessential mass gatherings and the implementation of work from home, stay at home and other quarantine directives. The potential impact and duration of the COVID-19 pandemic has had, and continues to have, a significant adverse impact across regional and global economies and financial markets. The global impact of the outbreak has been rapidly evolving and as new cases of the virus have continued, particularly in the U.S., countries around the world and states around the U.S., have reacted by instituting quarantines and restrictions on travel.

~~Table of Contents~~

Almost every state implemented shelter-in-place or stay-at-home directives between March and May 2020, including, among others, Los Angeles and San Bernardino counties, and the state of California, where we operate. The lockdown restrictions implemented included quarantines, restrictions on travel, shelter-in-place orders, school closures, restrictions on types of business that may continue to operate, and/or restrictions on types of construction projects that could continue. These quarantines generally came with exceptions for essential healthcare and public health operations, among other essential businesses. Beginning in early May 2020, the U.S. began to lift the lockdown restrictions and allow for the reopening of businesses. The gradual reopening of retail, manufacturing, and office facilities came with required or recommended safety protocols. There is no assurance that the reopening of businesses, even if those businesses adhere to recommended safety protocols, will enable us or our subsidiaries, VIEs, affiliated IPAs, contracted physician groups, service providers and suppliers to avoid adverse effects on our or their operations and businesses. Due to the increase in the number of COVID-19 cases after the reopening of many states beginning in early June 2020, there is no assurance that local and state governments will not reinstitute new lockdown directives.

In order to protect our employees, we have implemented a number of precautionary measures, including a work from home policy, under which the vast majority of our employees currently operate. To date, such measures have not had a substantial impact on employee attendance or productivity, and have not adversely affected our ability to recruit, attract or retain skilled personnel. Our operations, including our ability to effectively provide management services to our affiliated IPAs and contracted physician groups in compliance with regulatory requirements have not been impacted, however, if the outbreak continues to worsen it may cause disruptions to critical infrastructures and our supply chains and the supply chains of our affiliated IPAs and contracted physician groups, including the supply of pharmaceuticals and medical supplies. The duration and extent of the impact from the coronavirus outbreak depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus, the extent and effectiveness of containment actions. If we are not able to respond to and manage the impact of such events effectively, our business could be harmed.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~During~~None for the three months ended September 30, 2020, the Company issued an aggregate of 499,663 shares of common stock and received approximately $3,404,374 from the exercise of certain warrants at exercise prices ranging between $9.00 and $10.00 per share. The foregoing issuances were exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof, and/or Regulation D promulgated thereunder.2021.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.

~~Table of Contents~~


Exhibit No.						Description

2.1†						Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (the “Merger Agreement”) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)

2.2						Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)

2.3						Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)

~~2.4~~†2.4†						Stock purchase agreement dated March 15, 2019~~(incorporated~~ (incorporated herein by reference to Exhibit 2.4 to the Company’s Quarterly Report on Form 10-Q filed on May 10, 2019)

3.1						Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 21, 2015)

3.2						Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 27, 2015)

3.3						Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 13, 2017)

3.4						Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 21, 2018)

3.5						Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on November 16, 2015)

3.6						Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on December 13, 2017)

3.7						Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on June 21, 2018)

4.1						Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 19, 2015).

4.2						Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 4, 2016).

4.3						Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).

4.4						Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).

4.5						Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).

4.6						Common Stock Purchase Warrant (“Series A Warrant”) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 19, 2015).


4.7						Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).

4.8						Common Stock Purchase Warrant (“Series B Warrant”) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 4, 2016).

4.9						Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).

4.10						Description of Registered Securities

31.1*						Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*						Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.3*						Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32**						Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*						XBRL Instance Document

101.SCH*						XBRL Taxonomy Extension Schema Document

101.CAL*						XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*						XBRL Taxonomy Extension Definition Linkbase

101.LAB*						XBRL Taxonomy Extension Label Linkbase Document
101.PRE*						XBRL Taxonomy Extension Presentation Linkbase Document

104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*						Filed herewith.

**						Furnished herewith

†						The schedules and exhibits thereof have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.

6968

~~Table of Contents~~

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	APOLLO MEDICAL HOLDINGS, INC.

Dated: November ~~9, 2020~~5, 2021	By:	~~/s/ Kenneth Sim~~
		Kenneth Sim, M.D. Executive Chairman & Co-Chief Executive Officer (Principal Executive Officer)

~~Dated: November 9, 2020~~	~~By:~~	/s/ Thomas Lam
		Thomas Lam, M.D., M.P.H. Co-Chief Executive Officer & President (Principal Executive Officer)

Dated: November ~~9, 2020~~5, 2021	By:	/s/ Brandon Sim
		Brandon Sim Co-Chief Executive Officer (Principal Executive Officer)

Dated: November 5, 2021	By:	/s/ Eric Chin
		Eric Chin Chief Financial Officer ~~and Interim Co-Chief Operating Officer~~ (Principal Financial Officer)

7069


	Useful Life (Years)	Gross September 30, 2020		Accumulated Amortization		Net September 30, 2020
Amortized intangible assets:
Network relationships	11-15	$	143,930	$	(70,200)	$	73,730
Management contracts	15	22,832		(11,225)		11,607
Member relationships	12	6,696		(3,013)		3,683
Patient management platform	5	2,060		(1,167)		893
Trade names/trademarks	20	1,011		(143)		868
		$	176,529	$	(85,748)	$	90,781


	Useful Life (Years)	Gross December 31, 2019		Accumulated Amortization		Net December 31, 2019
Amortized intangible assets:
Network relationships	11-15	$	143,930	$	(60,526)	$	83,404
Management contracts	15	22,832		(9,676)		13,156
Member relationships	12	6,696		(2,352)		4,344
Patient management platform	5	2,060		(858)		1,202
Trade names/trademarks	20	1,011		(105)		906
		$	176,529	$	(73,517)	$	103,012


	Amount

2020 (excluding the nine months ended September 30, 2020)	$	3,798
2021	14,524
2022	12,673
2023	10,842
2024	9,830
Thereafter	39,114

Total	$	90,781


	Four Months Ended April 30, 2020		Nine Months Ended September 30, 2019

Revenues	$	195,308	$	372,181
Expenses	189,028		370,597

Income before benefit from income taxes	6,280		1,584
Benefit from income taxes	0		(11,010)

Net income	$	6,280	$	12,594


	For the Nine Months Ended September 30,
	2020		2019		$ Change		% Change
Revenue
Capitation, net	$	416,402	$	305,548	$	110,854	36	%
Risk pool settlements and incentives	54,155		32,640		21,515		66	%
Management fee income	26,212		27,867		(1,655)		(6)	%
Fee-for-services, net	9,434		12,059		(2,625)		(22)	%
Other income	4,194		3,753		441		12	%
Total revenue	510,397		381,867		128,530		34	%

Operating expenses
Cost of services	402,106		315,925		86,181		27	%
General and administrative expenses	39,660		30,031		9,629		32	%
Depreciation and amortization	14,004		13,793		211		2	%
Provision for doubtful accounts	—		(1,363)		1,363		(100)	%
Impairment of intangibles	—		1,994		(1,994)		(100)	%
Total expenses	455,770		360,380		95,390		26	%

Income from operations	54,627		21,487		33,140		154	%

Other income (expense)
Income from equity method investments	3,291		1,162		2,129		183	%
Gain on sale of equity method investment	99,647		—		99,647
Interest expense	(8,007)		(1,350)		(6,657)		493	%
Interest income	2,544		1,305		1,239		95	%
Other income	1,514		2,832		(1,318)		(47)	%
Total other income, net	98,989		3,949		95,040		*

Income before provision for income taxes	153,616		25,436		128,180		*

Provision for income taxes	44,204		6,483		37,721		*

Net income	109,412		18,953		90,459		477	%

Net income attributable to noncontrolling interests	81,603		11,564		70,039		*

Net income attributable to Apollo Medical Holdings, Inc.	$	27,809	$	7,389	$	20,420	276	%


Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA
	Year Ending
	December 31, 2020
(in thousands)
	Low		High
Net income(1)	$	110,000	$	120,000
Depreciation and amortization	19,000		20,000
Provision for income taxes	46,000		47,000
Interest expense	10,000		11,000
Interest income	(3,000)		(4,000)
EBITDA(1)	182,000		194,000

Income from equity method investments (2)	(100,000)		(99,000)
EBITDA adjustment for recently acquired IPAs	15,000		17,000
Adjusted EBITDA	$	97,000	$	112,000


	September 30, 2020		December 31, 2019

Cash and cash equivalents	$	23,957	$	23,013
Investment in marketable securities	118,187		116,853
Land, property and equipment, net	5,096		5,137
Investments in other entities - equity method	17,070		18,360

Total Excluded Assets	$	164,310	$	163,363